Document:

Exhibit 10.1

 Exhibit 10.1 
 [*** Certain confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission (the “Commission”) pursuant to a confidential treatment request in
accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. The location of each omitted portion is indicated by a series of three asterisks in brackets (“[***]”).] 

SUPPLY AGREEMENT 
 This Supply Agreement (this “Agreement”) is entered into as of August 8, 2011 (the “Effective Date”) by and between ZYNESHER PHARMACEUTICALS (USA), LLC, a Missouri
limited liability company (“Supplier”), and K-V PHARMACEUTICAL COMPANY, a Delaware corporation (“Customer”). 
 WHEREAS, Supplier and Customer are parties to an Asset Purchase Agreement dated as of June 17, 2011 (the “APA”); 

WHEREAS, pursuant to this Agreement, Supplier is obtaining certain assets to be used in the production of the Products (as defined below)
for Customer; and 
 WHEREAS, pursuant to Sections 5.02(a) and (b) and Section 8.09 of the APA, Supplier and Customer
have agreed to enter into this Agreement for the supply of Products by Supplier to Customer. 
 THEREFORE, in consideration of
the mutual promises and agreements made herein, the parties agree as follows: 
  

	1.	Definitions 

 Certain
capitalized terms used in this Agreement, when so used, mean the following: 
 “Act” means the United States
Federal Food, Drug, and Cosmetic Act and the rules and regulations thereunder, as amended and supplemented from time to time. 

“Adulterated Product” means any product which is adulterated or misbranded within the meaning of the Act, or any product
which may not be introduced into interstate commerce under the Act. 
 “Affiliate” means, with respect to any
Person, another Person that directly or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with such Person. 
 “Approval Date” means, with respect to a Product, the date that the FDA issues a final approval for such Product and the manufacture of such Product at Supplier’s facility.

 “Contract Year” means the 12 calendar month period commencing on the Effective Date and ending on the first
anniversary of the Effective Date and each successive 12 month period thereafter during the term of this Agreement. 

“Control” and, with correlative meanings, the terms “Controlled by” and “under common Control” means
the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of more than 50% of voting securities, by contract, resolution, regulation or otherwise. 

 “Customer Know-How” means the Product formulations and all Technology and
all other technical and clinical information, data and know-how related to the development, formulation, manufacture, packaging, use, testing or regulatory approval of the Products, including (but not limited to), trade secrets, designs, research
and development, results, analytical methods, laboratory notebooks, assays and results, techniques, derivations, processes, dosage forms, concepts, ideas, preclinical, clinical, biological, chemical, pharmacological, toxicological, pharmaceutical or
other data and results, validation information, stability history, experimental methods and results, manufacturing methods, physical and analytical safety, testing and quality control data and results, product specifications, in vivo data, material
supplier information, test methods for raw materials, components, work-in-process and finished product, stability, descriptions, specifications, scientific plans, depictions, inventions, discoveries, new technologies, product ideas, modifications,
improvements and extensions, supplier information, medical support information (including databases), all regulatory applications, filings and approvals and copies of all correspondence and other communications, memoranda or notes related thereto
with the FDA or any other regulatory authority pertaining thereto, adverse effects or experiences, expert opinions and analyses, the Product Dossier, the Regulatory Dossier, the Specifications, and any other written, printed or electronically stored
information and materials, including combinations or applications thereof, data summaries and compilations of data, and any and all other intellectual property, whether or not patentable, in each case as and to the extent relating to the
development, manufacture, testing, import, export, use, marketing, sale, distribution or regulatory approval of the Products, either used, owned or controlled by Customer. 
 “Customer-Owned Equipment” means the equipment listed on Appendix A. 
 “FDA” means the United States Food and Drug Administration and any successor agency having substantially the same function. 

“GMP” means all laws, guidelines and regulations applicable to the manufacture of the Products, including the current
Good Manufacturing Practices as specified in the United States Code of Federal Regulations, as the same may be amended and supplemented from time to time. 
 “Person” means any natural person, corporation, limited liability company, partnership or other entity. 
 “Products” means (a) Customer’s Gynazole•1® (butoconazole nitrate) Vaginal Cream, 2%, and (b) Customer’s Clindesse® (clindamycin phosphate) Vaginal Cream,
2%. 
 “Product Dossier” means Customer’s product dossier for the Products. 

“Purchase Price” means the purchase price for Product, as determined by Supplier and agreed to by Customer, calculated
in manner consistent with the principles agreed to by the parties and set forth in Appendix E as the costs directly attributable to Product materials, Product testing and stability, materials provided by Supplier in accordance with Appendix D,
direct and indirect labor and applicable overhead (direct and indirect) allocated to the Product based on facility utilization plus [***] percent ([***]%). 
 “Regulatory Dossier” means Customer’s product dossier for regulatory approval of the Products. 

  

					
		 	-2-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 “Specifications” means the product and packaging specifications for each
Product set forth in Appendix B, as amended from time to time in accordance with Section 2.7. 
 “Technical Support Term
Sheet” means the Technical Support Term Sheet attached hereto as Appendix G and incorporated herein in accordance with Section 17.9. 
 “Technical Support Timeline” means the timeline attached hereto as Appendix H. 
 “Technology” means public and nonpublic technical or other information, trade secrets, know-how, processes, formulations, concepts, ideas, preclinical, clinical, pharmacological or other
data and testing results, all experimental or test methods, laboratory notebooks, results, assays, descriptions, all scientific plans, depictions, inventions, processes, manufacturing methods, physical and analytical safety, testing and quality
control data and results, customer lists, marketing information, sales information, and any other written, printed or electronically stored information and materials and any and all other intellectual property, including patent rights, of any nature
whatsoever; in each case as and to the extent, but only as and to the extent, the same relates to the Products. For the avoidance of doubt, “Technology” includes Customer’s Site
Release® drug delivery system. 
 “Technology Transfer” means the transfer of information from Customer to Supplier necessary for Supplier to complete submission batch production of the Products as set forth in the
documents listed in Appendix F to this Agreement, which shall include technology transfer protocols and documentation mutually acceptable to Customer and Supplier. 

“Trademarks” means the trademark Gynazole-1® and the trademark Clindesse®.

 “Unit” means a vaginal applicator filled with Product and packaged in a tray with unit wrapping and carton
in accordance with the Specifications. 
  

	2.	Technology Transfer; Purchase and Sale of Products; Forecasts 

 2.1. On or as soon as practicable after the Effective Date, Customer shall transfer to Supplier all Customer Know-How and effectuate the Technology Transfer, including final pharmaceutical development
reports for the Products, in each case to the extent necessary and appropriate for the manufacture of the Products in accordance with this Agreement. In addition, Customer shall make available to Supplier the Customer-Owned Equipment.
Supplier’s obligation to manufacture Products shall be subject to (x) the Technical Support Term Sheet, and (y) the transfer of all necessary and appropriate Customer Know-How to Supplier. Customer shall be responsible to ensure the
effectiveness of the Technology Transfer so as to permit Supplier to produce said Product in accordance with FDA requirements. 

2.2. Without limiting the generality of Section 2.1, Customer shall make available to Supplier (a) copies of all applicable
requirements, standards, policies, reports and report formats, user manuals, technical manuals, system architecture, processes, operating procedures and other documentation, including but not limited to stability testing, in vitro comparison
studies, compounding work, analytical method transfer and the like, (b) copies of flow charts of the manufacturing procedures and work instructions related to manufacturing the relevant Product, (c) a list of all material equipment,
including the source of such equipment, utilized in the 

  

					
		 	-3-	 	

 
production of the applicable Product, (d) copies of all current Specifications, including packaging, for the relevant Product, (e) copies of all standard operating procedures for the
manufacturing procedures, (f) all necessary environmental conditions necessary to manufacture the relevant Product and copies of any existing external environmental impact studies based on the materials or methods employed in the manufacturing
method to be made available to Supplier, and (g) such other documentation as the parties hereto may agree. To the extent commercially practicable, Supplier shall use those Hired Employees (as defined in the APA) who were involved in the
production of the Products prior to the Effective Date in corresponding roles for Supplier in the performance of its obligations under this Agreement. 
 2.3. At Customer’s written request, Supplier agrees to use commercially reasonable efforts to assist Customer in qualifying a secondary site as an FDA-approved manufacturing facility. 

2.4. Pursuant to the terms and conditions of this Agreement, from and after the applicable Approval Date, Supplier shall manufacture,
package and sell Product to Customer in response to and in compliance with purchase orders delivered by Customer to Supplier. Supplier will supply Product in batch sizes. Customer shall take delivery of at least a batch of the Product. 

2.5. Customer shall supply the items set forth on Appendix C in sufficient quantities to enable Supplier to produce Products for Customer
in accordance with the Forecasts (as defined below) and to cover yield, failed batches, expired ingredients, and any other losses occurring in the normal course of business. Customer represents and warrants that the items set forth on Appendix D are
the only items that are required to be supplied by Supplier in order to produce the Products in light of the items set forth on Appendix C being supplied by Customer. 
 2.6. Customer will deliver purchase orders to Supplier not less than 120 days before the delivery date(s) of the Products required by Customer. Each order will be for at least one or more whole batches of
the Products, as provided in the Specifications. Supplier will deliver each order so that Customer receives the ordered Products on or about the delivery date(s) requested (but in no event later than seven days after the requested delivery date(s)).
Customer shall accept delivery of all Products ordered pursuant to the purchase orders made as of the termination or expiry of this Agreement. 
 2.7. Customer will provide Supplier by the end of each calendar quarter with a written forecast of its Product requirements (“Forecast”), broken down by each forthcoming quarter, for the
following 12 months. If a Forecast calls for average weekly purchases in excess of the quantities normally produced at Supplier’s facilities by one shift in a normal five-day week, and Supplier lacks the capacity to manufacture Product in the
quantities set forth in such Forecast, Supplier may within 30 days of receipt of the Forecast notify Customer of Supplier’s capacity constraints and indicate the approximate quantities of Product that Supplier can supply (which quantities shall
be at least the quantities normally produced at Supplier’s facilities by one shift in a normal five-day week) (the “Supplier Notice”). During a calendar quarter, Customer shall submit purchase orders for not less than [***]% or
more than [***]% of the Product quantities for that quarter set forth in the most recent Forecast or the Supplier Notice, as applicable. All Product orders must represent full batch quantities. 

  

					
		 	-4-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 2.8. Customer will communicate to Supplier in writing any changes to the Specifications. In
the event that the new Specifications increase Supplier’s costs, then the parties shall negotiate and agree in good faith on any changes to the Purchase Prices required to keep Supplier whole before the Specification changes take effect.

 2.9. Within thirty (30) days after Customer determines that any Product is defective in material or workmanship, or is
not in conformance with applicable Specifications, or is an Adulterated Product (Product not meeting any or all of the foregoing being hereinafter referred to as “Defective Product”), Customer may reject and return any such
Defective Product to Supplier. Any Product received by Customer from Supplier that has not been rejected by Customer within such thirty (30) day period shall be deemed to have been accepted. At the time of any rejection of any Product, Customer
shall provide Supplier with a written notice describing in detail the circumstances surrounding the rejection and Customer’s reasons therefor (“Rejection Notice”). Within twenty (20) days after its receipt of any Rejection
Notice, Supplier shall notify Customer of its disagreement or agreement with respect to the rejection set forth in the Rejection Notice (“Supplier Notice”). If Supplier timely provides Customer with a Supplier Notice of disagreement
with the rejection of any Product by Customer, the parties shall submit samples of such Product to an independent laboratory agreed upon by both parties and such laboratory’s determination as to whether or not the Product rejected by Customer
was Defective Product and whether Customer rightfully rejected the Product shall be final and binding upon the parties. The costs and expenses of any such independent laboratory analysis shall be paid for by the non-prevailing party. If it is
finally determined that any rejected Product is not a Defective Product, Customer shall accept such Product and pay the Purchase Price applicable thereto, if not already paid. Upon final determination or agreement that a Product is a Defective
Product, Customer will, at the option of Supplier, either return such Defective Product to Supplier for disposal or destroy or dispose of it in the least expensive and most environmentally sound manner and, in either event, Supplier shall be
responsible for the costs of any such return, destruction or disposal. The amount already paid by Customer to Supplier for any Defective Product that is returned, destroyed or disposed of in accordance herewith shall be refunded by Supplier to
Customer within 3 business days of receipt of written request for refund by Supplier from the Customer 
 2.10. Upon
Customer’s reasonable request, Supplier agrees to supply Customer with any material information and data relating to the Products which may be or become available to Supplier throughout the term of this Agreement. Supplier shall not contest
Customer’s use of such material information and data for the purpose of Customer’s own business interests anywhere in the world. Furthermore, each party agrees to inform the other party as soon as practicable of any material fact or
circumstance, whether of scientific, legal or other nature, which may affect the manufacturing, marketing or sale of the Products. 
 2.11. In the absence of an assertion by Customer that Product is Defective Product, if Customer refuses to take delivery of any Product manufactured by Supplier in accordance with Customer’s purchase
order, Customer shall be responsible for payment of the applicable Purchase Price with respect to such Product. 

  

					
		 	-5-	 	

	3.	Representations, Warranties and Covenants 

 3.1. Supplier represents and warrants to Customer that all Products delivered to Customer shall: (a) comply in all respects with the Specifications for that Product; (b) not be Adulterated
Product; (c) conform to all applicable FDA regulations, GMP and any comparable state agency requirements applicable thereto and will be labeled in accordance with applicable regulations and Customer’s reasonable requirements; (d) be
packaged using Customer’s approved and marketed trade dress for the outer carton and contents of the Product; (e) not contain a patent or latent defect, unless such defect arises from the Specifications; and (f) be free and clear of
all liens, security interests and other encumbrances. 
 3.2. Supplier represents and warrants to Customer that from and after
the applicable Approval Date, Supplier, its employees, officers, directors agents and representatives, and the facilities used to manufacture the Products are and shall at all times during the term of this Agreement remain properly qualified under
and in compliance with all applicable laws, rules and regulations to the extent required in order for Supplier to fulfill its obligations under this Agreement. 
 3.3. Supplier agrees to comply with the requirements of the Quality Agreement in the performance of its obligations hereunder. In the event of any conflict between the Quality Agreement and this
Agreement, the Quality Agreement will control as to all quality matters and this Agreement will control as to all other matters including, without limitation, business, legal and financial matters. 

3.4. Supplier represents and warrants to Customer that the execution, delivery and performance of this Agreement by Supplier does not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, and does not violate any law, regulation or order of any court, governmental body or administrative or other agency having
authority over it; and during the term of this Agreement Supplier will not enter into any agreements, oral or written, that are inconsistent with its obligations under this Agreement. 

3.5. Supplier is validly existing and in good standing under the laws of the state of its incorporation or organization and has the
limited liability company power and authority to enter into this Agreement. This Agreement has been duly executed and delivered by Supplier and constitutes the valid and binding obligation of Supplier, enforceable against it in accordance with its
terms. The execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of Supplier. 
 3.6. Supplier shall maintain quality assurance procedures in accordance with the Quality Agreement. 
 3.7. Supplier shall provide Customer with notice of any non-confidential communications with licensing boards or the FDA which relate to material problems with facilities, operations or procedures used by
Customer in its distribution of the Products. Supplier shall notify Customer immediately upon receipt of notice of any inspection by the FDA or directed any notices, requests for information or other communications related to the Products.

  

					
		 	-6-	 	

 3.8. Customer represents and warrants to Supplier that the execution, delivery and
performance of this Agreement by Customer does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, and does not violate any law, regulation or order of any court,
governmental body or administrative or other agency having authority over it; and during the term of this Agreement Customer will not enter into any agreements, oral or written, that are inconsistent with its obligations under this Agreement.

 3.9. Customer is validly existing and in good standing under the laws of the state of its incorporation or organization and
has the corporate power and authority to enter into this Agreement. This Agreement has been duly executed and delivered by Customer and constitutes the valid and binding obligation of Customer, enforceable against it in accordance with its terms.
The execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of Customer. 
 3.10. The terms of this Article 3 shall survive the termination of this Agreement, for any reason. 
  

	4.	Ownership and Use of Customer-Owned Equipment, Customer Know-How and Trademarks 

4.1. Supplier hereby agrees that Customer has and retains title to the Customer-Owned Equipment and that the Customer-Owned Equipment will
be used by Supplier solely to perform its obligations under this Agreement. Supplier shall ensure that the Customer-Owned Equipment is at all times during the term of this Agreement clearly identified as Customer’s property on plates attached
to the Customer-Owned Equipment or as otherwise reasonably specified by Customer. Supplier will be responsible for maintenance of the Customer-Owned Equipment and shall ensure that the Customer-Owned Equipment is in good working condition at all
times during the term of this Agreement. Such maintenance shall include, without limitation, lubrication, calibration and compliance with preventive maintenance procedures specified by the manufacturer or by Customer. Subject to Supplier’s
compliance with its maintenance obligations, Customer will be responsible for the costs of any required repairs (whether in- or out-of-warranty) to and replacement of the Customer-Owned Equipment; however, Supplier shall perform such repairs and/or
replacements at Customer’s direction. Supplier may not move, or cause or permit to be moved, the Customer-Owned Equipment from Supplier’s manufacturing facility without the prior written consent of Customer. In addition, Supplier shall
obtain and maintain all risk property insurance covering the Customer-Owned Equipment against physical loss or damage with coverage in an amount equal to at least the replacement value of the Customer-Owned Equipment from an insurance company
reasonably acceptable to Customer. Upon the termination, cancellation or expiration of this Agreement for any reason, Customer shall promptly, but in any event not later than 60 days after such termination, cancellation or expiration, dismantle,
package and remove the Customer-Owned Equipment, and Supplier shall at Customer’s expense grant Customer access to Supplier’s facilities to permit such dismantling, packaging and removal, and shall provide such other cooperation as
Customer may reasonably request in connection with such activities. 

  

					
		 	-7-	 	

 4.2. Supplier agrees that the Customer Know-How and the Trademarks and any related
trademark, trade name and/or trade dress and all other interests in and rights to the Products and their packaging or relating to the manufacture, marketing, use, packaging, sale and distribution of the Products, belong to Customer. Supplier shall
assure and hereby guarantees that any officer, director, employee or agent of Supplier or its Affiliates who is or claims to be the author, inventor or developer of any of the foregoing has assigned and will assign and transfer all rights in and to
the same to Customer during the term of this Agreement and upon the termination, expiration or cancellation of this Agreement, for any reason. Customer hereby grants to Supplier a non-exclusive license to use the Customer Know-How and Trademarks for
the sole purpose of producing Products for Customer under this Agreement. Supplier shall not use the Customer Know-How or Trademarks to develop, market, sell or distribute any other products or for any purpose other than the performance of its
obligations hereunder. Except as otherwise expressly provided in this Agreement, upon the termination, expiration or cancellation of this Agreement, for any reason, the license granted in this paragraph shall terminate and all rights to the Customer
Know-How, the Trademarks and any other trademark, trade name and trade dress and all other interests in and rights to the Products or relating to the manufacture, marketing, use, packaging, sale and distribution of the Products, shall remain with or
revert to Customer, as applicable, with no payment or other obligation of Customer to Supplier, its Affiliates or its or their officers, directors, employees or agents, and Supplier shall promptly transfer and deliver, or cause the transfer and
delivery of, all of the same to Customer and transfer and/or assist Customer in transferring or obtaining all government approvals required in connection with such transfer. 

 

	5.	Product Recalls 

 5.1. In
the event that (a) any government authority issues a request, directive or order that Products be recalled, (b) a court of competent jurisdiction orders such a recall, or (c) Customer and Supplier jointly determine that Products
should be recalled, the parties shall take all appropriate corrective actions as jointly determined by Supplier and Customer, and shall cooperate with each other in the investigations surrounding the recall. In the event that Customer and Supplier
do not jointly agree whether a recall is necessary after consultation, Customer shall have the final determination on whether or not to issue such recall and Supplier agrees to cooperate with Customer during the recall process, subject to all
applicable FDA regulations. 
 5.2. To the extent that a recall, withdrawal, field correction, or governmental seizure of
Product is due to (i) the failure of Product to conform to applicable Specifications, (ii) the failure of Supplier to comply in any material respect with its obligations hereunder or with any applicable law, rule, regulation, standard,
court order or decree, standard operating procedure, or GMP, or with Customer’s consent decree with the FDA, or (iii) the gross negligence or intentionally wrongful act or omission by Supplier in its manufacturing of any Product or in its
performance of its obligations hereunder, then Supplier shall bear the cost and expense of any such recall, withdrawal, field correction or seizure, and upon demand from Customer shall promptly indemnify Customer in accordance with Section 12
for costs and expenses incurred by Customer in connection therewith. To the extent that a recall, withdrawal, field correction, or governmental seizure of Product is due to any other reason, including, without limitation, the Specifications or
Customer Know-How. Customer shall bear the cost and expense of such recall, withdrawal, field correction or seizure, and upon demand from Supplier shall promptly 

  

					
		 	-8-	 	

 
indemnify Supplier in accordance with Section 12 for costs and expenses incurred by Supplier in connection therewith. Should a party become aware of a Product seizure or of facts and
circumstances that might justify the recall or withdrawal of or corrective action with respect to a Product, that party will notify the other party promptly of the details regarding such action, including providing copies of all relevant
documentation concerning such action or facts. The parties will cooperate in investigating any such situation, and all regulatory contacts that are made and all activities concerning seizure, recall, withdrawal or field correction will be initiated
and coordinated jointly. 
 5.3. Subject to Sections 5.1 and 5.2, except as otherwise required by law or governmental
regulation, Customer will be solely responsible for investigating and responding to all inquiries, complaints and adverse events regarding Products. Supplier agrees to provide such assistance as Customer shall reasonably request and, if requested by
Customer, Supplier agrees to lead investigations related to such at its facilities. 
 5.4. As soon as either party becomes
aware, it shall give the other party prompt written notice of any defect or alleged defect in a Product, any injury alleged to have occurred as a result of the use or applicable of a Product, and any circumstances that may reasonably be expected to
give rise to litigation or recall of a Product or regulatory action that may affect the sale or manufacture of a Product, specifying, to the extent known, the time, place and circumstances thereof and the names and addresses of the Persons involved.
Each party shall also furnish promptly to the other party copies of all papers received in respect of any claim, action or suit arising out of such alleged defect, injury or regulatory action. 

5.5. If Supplier concludes that Product cannot consistently meet Specifications, or if Customer or the FDA requires changes that Supplier
cannot reasonably implement, then Supplier will work in good faith with Customer to test and implement reasonable changes at Customer’s request in order to consistently meet the Specifications or such requirements, if possible. 

 

	6.	No Sales to Other Persons 

Supplier agrees not to develop, market, sell or distribute the Products, or any products competitive with the Products, directly or
indirectly, to any Persons other than Customer. 
  

	7.	Product Prices 

 7.1. The
initial Purchase Prices of the Products will be as set forth on Appendix E. For the avoidance of doubt, the parties agree that any validation batches of Clindesse produced by Customer prior to the date of this Agreement shall remain the property of
Customer and shall not be considered “Product” for which payment of the Purchase Price is due. 
 7.2. Following the
expiration of [***] calendar months after the Approval Date, Supplier may increase the Purchase Prices (taking into account the factors referenced in the definition of “Purchase Price) on at least 60 days’ advance written notice. Supplier
will supply Products based on maximum [***] production campaigns per calendar year. If Customer, during a calendar year, wants more than [***] campaigns, Supplier reserves the right to revise the applicable Purchase Price(s) to reflect documented
increases in its overhead expenses resulting therefrom. 

  

					
		 	-9-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 7.3. Following the completion of each [***]-month period from and after the Approval Date,
Supplier shall reconcile its costs of production (using the factors taken into account per the “Purchase Price” definition) of each Product for such [***]-month period and the aggregate Purchase Price paid for that Product during such
[***]-month period. In the event that the aggregate Purchase Price paid for such Product in such [***]-month period is less than such costs of production plus [***] percent ([***]%), Supplier shall invoice Customer, and Customer shall pay Supplier,
an amount equal to such deficiency. In the event that the aggregate Purchase Price paid for such Product in such [***]-month period is more than such costs of production plus [***] percent ([***]%), Supplier shall provide written notice of same to
Customer, and Supplier shall pay Customer an amount equal to such excess. Customer shall have the right (but not the obligation) to audit and inspect Supplier’s records with respect to Supplier’s costs of production in order to verify such
costs. This right shall survive the expiration or termination of this Agreement for a period of [***] with respect to such costs incurred during the term of this Agreement. 
 7.4. All amounts payable hereunder by Customer to Supplier shall be paid in full and shall not be subject to (i) set-off of any amounts due from Supplier to Customer, or (ii) deduction,
including deduction on account of any withholding tax obligations, if any. 
  

	8.	Certificate of Analysis 

Supplier will provide Customer a Certificate of Analysis with each Product shipment, evidencing compliance of the Product with the
Specifications. 
  

	9.	Terms of Sale 

 The
Product will be sold to Customer by Supplier hereunder [****]. Payment terms shall be [***] days from receipt of the invoice by Customer. 
  

	10.	Quality Agreement 

 The
parties agree to enter into a separate quality agreement (the “Quality Agreement”) within thirty (30) days following the Effective Date. The Quality Agreement shall delineate in further detail each party’s responsibilities
for documentation management and other aspects of the manufacturing of the Products in accordance with applicable laws and regulations. Both parties agree to comply with the requirements of the Quality Agreement during the term of this Agreement.

  

	11.	Adverse Drug Event Reporting 

 The Quality Agreement shall contain terms and conditions relating to safety data and exchange matters. 
  

	12.	Indemnification 

 12.1.
Subject to the limitations set forth in Section 12.4, Supplier shall indemnify Customer and its officers, directors, agents, employees, and Affiliates against all claims, actions, losses, damages, personal injuries (including death), costs,
expenses (including court costs and 

  

					
		 	-10-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 
legal fees) and other liabilities to the extent resulting from or caused by (i) the failure of Product to conform to applicable Specifications; (ii) the failure by Supplier to comply in
all material respects with any applicable law, rule, regulation, standard, court order or decree; or (iii) any gross negligence or intentionally wrongful act or omission by Supplier in its manufacturing of the Product or its performance
hereunder. Supplier shall not be liable for any claim, loss or damage resulting from improper storage, transportation or handling of the Products by Customer, its freight carrier and/or their respective representatives. The terms of this
Section 12.1 shall survive the termination or expiration of this Agreement for any reason. 
 12.2. Subject to the
limitations set forth in Section 12.4, Customer shall indemnify Supplier and its officers, directors, agents, employees, and Affiliates against all claims, including third party claims, actions, losses, damages, personal injuries (including
death), costs, expenses (including court costs and legal fees) and other liabilities resulting from or caused by (i) Customer’s breach of this Agreement; (ii) the non-conformity of the Specifications to any applicable FDA regulations,
GMP and or any comparable state agency requirements applicable thereto; (iii) acts of gross negligence of Customer or its officers, directors, agents, employees, or Affiliates; (iv) the non-compliance of the Product with the requirements
of the relevant Product NDA (and supplements thereto) except for non-compliance resulting from Supplier’s breach of this Agreement or acts of gross negligence, or (v) any Product liability, except for Product liability due to or to the
extent contributed by (x) a failure of Product to conform to applicable Specifications, (y) the failure by Supplier to comply in material respects with any applicable law, rule, regulation, standard, court order or decree, or
(z) gross negligence or intentionally wrongful act or omission of Supplier in its manufacturing of any Product or its performance hereunder. The terms of this Section 12.2 shall survive the termination or expiration of this Agreement for
any reason. 
 12.3. Excluding each party’s indemnification obligations under Section 12.1 or 12.2 of this Agreement,
neither party’s total liability to the other party under this Agreement shall exceed US$[***]. 
 12.4. EXCEPT IN CASES
INVOLVING WILLFUL MISCONDUCT OR GROSS NEGLIGENCE, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR PUNITIVE, EXEMPLARY, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR OTHER INDIRECT DAMAGES (INCLUDING WITHOUT LIMITATION LOST SALES, PROFITS, BUSINESS OR
GOODWILL) ATTRIBUTABLE TO ANY BREACH OR DEFAULT BY SUCH PARTY UNDER THIS AGREEMENT. 
  

	13.	Term; Default; Termination 

13.1. This Agreement is effective as of the Effective Date and will continue in effect for three (3) Contract Years. Thereafter, this
Agreement will be automatically renewed and continue for consecutive additional one (1) Contract Year renewal terms unless either party provides written notice of non-renewal to the other party at least one year prior to the end of the then
current term. 
 13.2. The failure by one party to comply with any of its respective obligations in this Agreement shall entitle
the other party to give the party in default written notice in order to cure 

  

					
		 	-11-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 
such default. If such default is not remedied within 60 days after receipt of such notice from the other party, the notifying party shall be entitled, without prejudice to any of its other rights
conferred to it by this Agreement, to terminate this Agreement by giving notice with immediate effect. The right of either party to terminate this Agreement as provided herein shall not be affected in any way by its waiver of or failure to take
action with respect to any previous default. Notwithstanding anything to the contrary contained herein, if Customer fails to pay the Purchase Price or any other amounts payable hereunder (x) within ten (10) days of the due date set forth
in this Agreement, or (y) by the due date on three consecutive invoices provided by Supplier or its Affiliates to Customer, Supplier shall give Customer written notice and Customer shall have thirty (30) days after receipt of such notice
to cure the payment default; provided, however, that Customer shall not have such right to cure more than three times in any calendar year. If such default is not cured in such thirty (30) day period, or immediately, if such cure period is not
applicable, Supplier may terminate this Agreement with immediate effect by written notice to Customer. 
 13.3. Either party may
terminate this Agreement with immediate effect by written notice to the other party if the other party becomes the subject of proceedings involving bankruptcy or insolvency, makes any assignment for the benefit of creditors, or fails to continue to
conduct its business in all material respects as heretofore conducted. 
 13.4. Customer may terminate this Agreement for
convenience at any time on not less than 90 days’ written notice to Supplier. 
 13.5. The expiration or termination of
this Agreement shall not affect any obligation of the parties arising from any provision of this Agreement prior to the expiration or termination or arising in connection with or as a result of such termination. It is hereby clarified that Customer
shall accept delivery of any and all Products that were ordered prior to the expiration or termination of this Agreement and shall pay the applicable purchase price for such Products 

13.6. Upon termination or expiration of this Agreement for any reason, Customer shall (a) pay the applicable purchase price to
Supplier for all finished Product, and (b) reimburse Supplier for its reasonable costs for all unused inventory of raw materials, packaging materials, work in progress and specific quality control reagents that Supplier has in stock or that
Supplier has ordered pursuant to non-cancellable purchase orders to meet its supply obligations to Customer under this Agreement as reflected in the most recent Forecast provided by Customer to Supplier. Upon receipt of payment from Customer,
Supplier will, at Customer’s option, destroy or deliver such inventory to Customer. In addition to the foregoing, upon termination of this Agreement by Customer pursuant to Section 13.4 hereof, [***]. 

 

	14.	Confidentiality 

 14.1.
Supplier acknowledges that it is receiving and will receive Confidential Information (as defined below) from Customer. All Confidential Information furnished prior to or during the term of this Agreement by or on behalf of Customer to Supplier shall
be kept confidential by Supplier. Supplier shall not make use of any such Confidential Information, or disclose any Confidential Information to any Person, except for purposes authorized by this Agreement, unless previously authorized in writing by
Customer to do so. However, Supplier 

  

					
		 	-12-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 
may disclose Confidential Information to Supplier’s officers, directors and employees who require the Confidential Information for the purposes contemplated by this Agreement, provided such
officers, directors and employees are subject to the same obligations of confidentiality as are applicable to Supplier with respect to such Confidential Information and provided further that Supplier shall be fully responsible for the compliance
with this Agreement by its officers, directors and employees. For the purposes hereof, “Confidential Information” shall mean information relating to the Product or otherwise to the subject matter of this Agreement, whether written,
electronic, oral or other tangible or intangible form, furnished to Supplier by Customer, directly or indirectly. For the purposes hereof, the Product Dossier and the Regulatory Dossier and information created by Supplier from or related to the
Confidential Information are expressly included in Customer’s Confidential Information. Supplier agrees not to make any copy of or extract from the Regulatory Dossier without Customer’s prior written consent. In addition, Supplier agrees
to take reasonable and appropriate actions to preserve the confidentiality of the Confidential Information. 
 14.2. The
obligations of confidence and nonuse provided in Section 14.1 shall not apply to information which: 
 (a) is, at the time
of disclosure, or thereafter becomes, part of the public domain through no fault or negligence of Supplier, or any or its existing or past officers, directors, employees or agents; 

(b) was in Supplier’s lawful possession prior to disclosure hereunder or under or in connection with the transactions contemplated
by the APA, as shown by its written records; 
 (c) is lawfully disclosed to Supplier on a non-confidential basis by a third
party who does not have an obligation of confidentiality to Customer hereunder relative to such information; or 
 (d) Supplier
is required to disclose as a requirement of law or in connection with any legal or regulatory proceeding or otherwise requested by any governmental agency or regulatory authority, including any self-regulatory organization having jurisdiction over
Supplier, provided that Supplier has provided reasonable prior notice of such required disclosure to Customer so that Customer has the opportunity to seek an appropriate protective order or other relief. 

For the purposes of this Agreement, information shall not be construed to be within one of the foregoing exceptions merely because it may be referred to
or otherwise generally included in disclosures of a broad nature or represents a technological advance or improvement of any Confidential Information, or because constituent elements or combinations thereof fall within one or more of the above
exceptions. 
 14.3. Supplier acknowledges that all inventions, discoveries, designs, developments, improvements, copyrightable
material, trade secrets and related Intellectual Property Rights (as defined below), which Supplier and Customer jointly may conceive, develop, or reduce to practice in connection with or based, directly or indirectly, on any Confidential
Information, shall be owned by Customer. The term “Intellectual Property Rights” shall include, without 

  

					
		 	-13-	 	

 
limitation, rights in relation to any trademarks, patents, designs, copyrights, and the rights to register and renew any of the aforesaid rights. Supplier undertakes to cooperate in good faith
and execute all such documents and do all such things as may be necessary or incidental to the implementation and performance of this provision. 
 14.4. Upon the termination, cancellation or expiration of this Agreement for any reason, Supplier agrees to promptly, but in any event not later than 30 days after such termination, cancellation or
expiration, return the Confidential Information to Customer and to destroy all memoranda or other documents or records, written or electronic, or other tangible forms which contain Confidential Information, provided that Supplier may retain an
archival copy of such Confidential Information for its record or as required by any applicable law, rule or regulation. 
 14.5.
The obligations of confidentiality and nonuse under this Article 14 are independent of all other rights and obligations of the parties under this Agreement or otherwise and shall continue beyond the termination, cancellation or expiration of this
Agreement for any reason. 
  

	15.	Compliance with Law 

Supplier covenants to Customer that Supplier and its directors, officers, employees and agents are, and during the term of this Agreement
shall at all times remain, properly qualified in accordance with all applicable laws, rules and regulations to perform the services contemplated to be performed by Supplier under this Agreement. Supplier covenants and agrees that the performance of
this Agreement by Supplier and its directors, officers, employees and agents will not conflict with and will in all respects be in compliance with all material laws applicable to such performance, except to the extent that the Specifications do not
comply with any applicable law. 
  

	16.	Warranties and Insurance 

16.1. Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SUPPLIER EXPRESSLY DISCLAIMS ALL REPRESENTATIONS OR WARRANTIES
OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY REPRESENTATION OR WARRANTY AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE
SPECIFICALLY DISCLAIMED HEREBY. 
 16.2. Insurance. Each of Customer and Supplier shall obtain and maintain at its
expense during the term of this Agreement and for five (5) years thereafter an insurance policy or policies written by insurance companies reasonably acceptable to the other party, covering products liability with respect to the Products and
general commercial liability and naming the other party as an additional insured, in the amount of no less than ten million dollars ($10,000,000). All such policies shall provide that coverage thereunder shall not be terminated or reduced without
the prior written consent of the other party. Each of Customer and Supplier shall furnish the other party with certificates of insurance and evidence of renewals. The purchase of such insurance or the furnishing of certificates shall not be in
satisfaction of a party’s liability hereunder or in any way modify either party’s indemnification obligations hereunder. 

  

					
		 	-14-	 	

	17.	Miscellaneous 

 17.1.
Audit Rights. At all times during and for a period of three (3) years following the term of this Agreement, Supplier shall maintain true and correct copies of all records and all correspondence relevant to this Agreement. During the term
of this Agreement and for a period of three (3) years thereafter, during normal business hours, Customer, or its independent auditor, shall be entitled to audit and inspect those books and records of Supplier that are maintained in connection
with the performance of Supplier’s obligations under this Agreement. 
 17.2. Independent Contractors. It is
understood between the parties that Supplier is an independent business entity otherwise unrelated to Customer. The parties to this Agreement are independent contractors and nothing contained in this Agreement shall be construed to place the parties
in the relationship of employer and employee, partners, principal and agent, or joint venturers. Neither party shall have the power to bind or obligate the other party. Except as expressly contemplated by this Agreement, neither party shall hold
itself out as representing the other party. 
 17.3. Force Majeure. Neither party shall be responsible or liable to the
other party for, nor shall this Agreement be terminated as a result of, any failure to perform any of its obligations hereunder, if such failure results from circumstances beyond the control of the party, including, without limitation, requisition
or seizure by any government authority, the effect of any statute, ordinance or governmental order or regulation enacted after execution of this Agreement, flood, hurricane, tornado, tsunami, earthquake or other natural calamities, wars, strikes,
lockouts, riots, disease, an act of God, civil commotion, terrorism, fire, failure of public utilities, common carriers or supplies, failure of vendors to deliver materials necessary for manufacturing the Products, including testing materials and
active pharmaceutical ingredients, failure of any machinery or equipment used for manufacturing of Products (other than as a result of Supplier’s failure to comply with its maintenance obligations hereunder), or any other circumstances, whether
or not similar to the above causes. The parties shall use their reasonable commercial efforts to avoid or remove any such causes and shall resume performance under this Agreement as soon as practicable whenever such cause is removed. 

17.4. Assignment. Neither Supplier nor Customer may assign, subcontract or otherwise transfer or encumber any of its rights or
obligations under this Agreement, by operation of law or otherwise, without the prior written consent of the other party, which consent may not be unreasonably withheld; provided, however, that either party may assign this Agreement to an Affiliate
without the other party’s consent. No assignment shall relieve the assignor of its obligations hereunder unless the other party otherwise agrees in writing. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit
of the parties and their respective permitted successors and assigns. 
 17.5. Amendment. If a party utilizes a purchase
order, order confirmation or similar document to release or confirm orders, the terms or conditions thereof shall not be applicable, except with respect to regular and ordinary order-specific terms such as dates of delivery or

  

					
		 	-15-	 	

 
quantities, and in the event of any conflict between any of them and this Agreement, the terms of this Agreement shall govern. No amendment or modification of this Agreement shall be binding on
either party unless it is in writing and signed by an authorized representative of such party. 
 17.6. Severability. If
any provision of this Agreement, under any set of circumstances, whether or not foreseeable by the parties, is hereafter held to be invalid, illegal or unenforceable in its present form and scope in any jurisdiction or proceeding: (a) to the
extent permitted by applicable law, the parties hereby waive any provision of law that would render any provision hereof prohibited or unenforceable in any respect, (b) in any event, the remaining provisions of this Agreement shall continue to
be given full force and effect, without regard to the invalid, illegal or unenforceable provision in such jurisdiction or proceeding and shall be liberally construed in order to carry out the intentions of the parties expressed herein as nearly as
possible, and (c) the parties agree that the court making such determination shall have the power, and is hereby directed, to alter or reduce such provision so that, in its altered or reduced form, the provision is enforceable and effective as
nearly as possible to the purposes expressed in this Agreement. Notwithstanding the foregoing, any such determination and amendment hereof by any such court, panel or authority shall be limited to the jurisdiction thereof and shall not affect the
validity, legality, enforceability or application of this Agreement in its existing form and scope in any other jurisdiction or proceeding. 
 17.7. Notices. Any notice to be given by either party shall be in writing, sent by express, registered or certified mail, postpaid, by generally recognized courier service (such as DHL or Federal
Express) or by confirmed telefax, to the attention of the Vice President, Business Development in the case of Customer and to Vice President-Operations in the case of Supplier, at the address of each party first set forth on the signature page
hereto or to such other address as a party shall give notice to the other in like manner, and shall be deemed to have been given or made as of the date so mailed or sent. For such purposes, the telefax number of Customer is 314-645-4705, and the
telefax number of Supplier is 609-730-1998. 
 17.8. Governing Law; Jurisdiction. 

(a) This Agreement shall be deemed to have been entered into and shall be governed by and construed under the laws of the State of
Delaware, except that no conflict of laws provision shall be applied to make the laws of any other jurisdiction applicable to this Agreement. The parties expressly waive and disclaim the application of the United Nations Convention on International
Sale of Goods to this Agreement. 
 (b) Any legal action on or relating to this Agreement shall be brought only in the federal
or state courts located in the State of Delaware. For the purpose of any such legal action, the parties expressly: (i) consent to the jurisdiction of the Delaware federal and state courts, and (ii) waive trial by jury. 

(c) If legal action is instituted, the parties waive personal service of process and consent to service of process in the manner provided
in Section 17.7. 

  

					
		 	-16-	 	

 (d) If legal action is taken by either party to enforce the terms of this Agreement, the
prevailing party shall be entitled to recover its reasonable attorneys’ fees and related costs. 
 17.9. Technical
Support. From and after the date hereof, until the Approval Date of a Product, with respect to such Product: (i) the obligations of the Parties shall be governed by the Technical Support Term Sheet attached hereto as Appendix G and the
terms and conditions of this Agreement, including the limitations of liability set forth herein; and (ii) in the event of a conflict between a provision set forth in the body of this Agreement and a provision set forth in the Technical Support
Term Sheet, the provision set forth in the Technical Support Term Sheet shall control. 
 [Remainder of page intentionally
left blank; signature page follows] 

  

					
		 	-17-	 	

 IN WITNESS WHEREOF, this Agreement has been executed on behalf of the parties as of the date
first set forth above. 
  

									
	ZYNESHER PHARMACEUTICALS (USA), LLC	 		 	K-V PHARMACEUTICAL COMPANY
					
	By:	 	/s/ JD Renner	 		 	By:	 	/s/ Gregory J. Divis, Jr.
					
	Name:	 	JD Renner	 		 	Name:	 	Gregory J. Divis, Jr.
					
	Title:	 	President	 		 	Title:	 	President and CEO
			
	Notice Address:	 		 	Notice Address:
			
	c/o Zydus Pharmaceuticals (USA), Inc.	 		 	K-V Pharmaceutical Company
	73 Route 31 N.	 		 	One Corporate Woods Drive
	Pennington, NJ 08534	 		 	Bridgeton, MO 63044
					
	Attn :	 	Prashant Desai	 		 	Attn:	 	Daniel J. Thompson
		 	Vice President-Operations	 		 		 	Vice President Medical Affairs
		 		 		 		 	& Business Development

  

					
		 	-18-	 	

 APPENDIX A 

CUSTOMER-OWNED EQUIPMENT 
  

			
	17575	  	VISION SYSTEM, HIGH SPEED
	17604	  	MIXER/AGITATOR, LIGHTNIN
	17606	  	MIXER/AGITATOR, LIGHTNIN
	18526	  	PRINT/APPLY PRINTER
	18684	  	MACHINE VISION SYSTEM
	18685	  	ENCLOSURE, VISION SYSTEM
	18686	  	SYSTEM CONTROL PANEL
	18773	  	PUMP, HUSKY DIAPHRAGM
	19346	  	COLLOID MILL, GREERCO
	20421	  	PUMP, METERING BRAN AND LUBBE
	9715	  	DOBOY WRAPPER
	9716	  	FILLER-CRÈME COMAS
	9857	  	KETTLE, STEAM 150 GALLON
	10442	  	PUMP, BARREL
	10443	  	CAP FEEDER VIBRATORY
	10445	  	TRAY LOADER
	10451	  	CHKWGHER, MT, VL-2,600gROMANCO
	10452	  	CARTONER-CAM
	10454	  	CASE PACKER-BERGAMI C97
	10535	  	CONVEYOR
	10538	  	CONVEYOR-PRINT AND APPLY
	11626	  	FEEDER, APPLICATION IN
	12625	  	PUMP, LIQUID TRANSFER
	14268	  	MIXER, AIR LIGHTNIN
	15846	  	TANK, 100 GAL
	15848	  	TANK, 100 GAL
	16252	  	CHECKWEIGHER, COMAS

  

					
		 	-19-	 	

 APPENDIX B 

SPECIFICATIONS 
 [***] 

  

					
		 	-20-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 APPENDIX C 

CUSTOMER-SUPPLIED ITEMS 
 KV Provided Materials (Quantity per batch) 
  

																									
	 	  	Clindesse®	  	 	 	  	 	 	  	 	 	  	Gynazole-1®	  	 	 	  	 	 
	 2-1111
	  	 Clindamycin [***]
	  	 	[***]	  	  	 	KG	  	  	 	2-1149	  	  	 Butoconazole [***]
	  	 	[***]	  	  	 	KG	  
	 TRADE
	  		  				  				  	 	TRADE	  	  		  				  			
	 P3221
	  	 Applicator Body 5g
	  	 	50000	  	  	 	EA	  	  	 	P3221	  	  	 Applicator Body 5g
	  	 	50000	  	  	 	EA	  
	 P3223
	  	 Applicator Tray
	  	 	50000	  	  	 	EA	  	  	 	P3223	  	  	 Applicator Tray
	  	 	50000	  	  	 	EA	  
	 P5262
	  	 Applicator Tip,Modified
	  	 	50000	  	  	 	EA	  	  	 	P5262	  	  	 Applicator Tip,Modified
	  	 	50000	  	  	 	EA	  
	 P4251-1
	  	 Carton,Clindesse
	  	 	50000	  	  	 	EA	  	  	 	P5305-1	  	  	 Foil Overwrap,Gynazole1
	  	 	50000	  	  	 	EA	  
	 P4252-2
	  	 Foil Overwrap,Clindesse
	  	 	50000	  	  	 	EA	  	  	 	P5306-1	  	  	 Carton,Gynazole-1 2% Cr
	  	 	50000	  	  	 	EA	  
	 P4250-2
	  	 Insert,Clindesse
	  	 	50000	  	  	 	EA	  	  	 	P4249-2	  	  	 Insert,Gynazole 1
	  	 	50000	  	  	 	EA	  
	 SAMPLE
	  		  				  				  	 	SAMPLE	  	  		  				  			
	 P3221
	  	 Applicator Body 5g
	  	 	50000	  	  	 	EA	  	  	 	P3221	  	  	 Applicator Body 5g
	  	 	50000	  	  	 	EA	  
	 P3223
	  	 Applicator Tray
	  	 	50000	  	  	 	EA	  	  	 	P3223	  	  	 Applicator Tray
	  	 	50000	  	  	 	EA	  
	 P5262
	  	 Applicator Tip,Modified
	  	 	50000	  	  	 	EA	  	  	 	P5262	  	  	 Applicator Tip,Modified
	  	 	50000	  	  	 	EA	  
	 P4745-1
	  	 Carton,Clindesse Sample
	  	 	50000	  	  	 	EA	  	  	 	P5307-1	  	  	 Carton,Gynazole 1 5gm C
	  	 	50000	  	  	 	EA	  
	 P4252-2
	  	 Foil Overwrap,Clindesse
	  	 	50000	  	  	 	EA	  	  	 	P5305-1	  	  	 Foil Overwrap,Gynazole1
	  	 	50000	  	  	 	EA	  
	 P4250-2
	  	 Insert,Clindesse
	  	 	50000	  	  	 	EA	  	  	 	P4249-2	  	  	 Insert,Gynazole 1
	  	 	50000	  	  	 	EA	  

  

					
		 	-21-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 APPENDIX D 

SUPPLIER-SUPPLIED ITEMS 
 Supplier provided materials (Quantity per batch) 
  

											
	 	  	 	  	Quantity per Batch	  	 	  	 	  	Quantity per Batch
	 	  	Clindesse	  	 	  	 	  	Gynazole-1	  	 
	 8-1590
	  	 Lecithin (Phospholipon G)
	  	[***]	  	8-128	  	 Propylene Glycol,USP
	  	[***]
	 8-1775
	  	 Polyglyceryl-3-Oleate,
	  	[***]	  	8-1775	  	 Polyglyceryl-3-Oleate,
	  	[***]
	 8-1776
	  	 Glyceryl Monoisostearat
	  	[***]	  	8-1776	  	 Glyceryl Monoisostearat
	  	[***]
	 8-1899
	  	 Methylparaben,NF (UENO)
	  	[***]	  	8-1899	  	 Methylparaben,NF (UENO)
	  	[***]
	 8-1900
	  	 Propylparaben,NF (UENO)
	  	[***]	  	8-1900	  	 Propylparaben,NF (UENO)
	  	[***]
	 8-216
	  	 Mineral Oil,USP(210CPS,
	  	[***]	  	8-216	  	 Mineral Oil,USP(210CPS,
	  	[***]
	 8-47
	  	 Sorbitol Solution,USP
	  	[***]	  	8-47	  	 Sorbitol Solution,USP
	  	[***]
	 8-51
	  	 Water,Purified USP
	  	[***]	  	8-51	  	 Water,Purified USP
	  	[***]
	 8-548
	  	 Wax,Microcrystalline,NF
	  	[***]	  	8-548	  	 Wax,Microcrystalline,NF
	  	[***]
	 8-672
	  	 Silica, Hydrophobic Col
	  	[***]	  	8-672	  	 Silica, Hydrophobic Col
	  	[***]
	 8-735
	  	 Edetate Disodium,USP/Ph
	  	[***]	  	8-735	  	 Edetate Disodium,USP/Ph
	  	[***]
						
	TRADE	  		  		  	TRADE	  		  	
	 P4253-1
	  	 Shpr/Label,Clindesse
	  	4165 EA	  	P3291-6	  	 Shpr/Label,Gynazole
	  	4165 EA
	 P3442-1
	  	 Shpr,12in 8-9/16x6x7-7/
	  	4165 EA	  	P3442-1	  	 Shpr,12in 8-9/16x6x7-7/
	  	4165 EA
						
	SAMPLE	  		  		  	SAMPLE	  		  	
	 P4775-1
	  	 Shpr/Label,Clindesse Sa
	  	4165 EA	  	P3625-6	  	 Shpr/Label,Gynazole 1S
	  	4165 EA
	 P3442-1
	  	 Shpr,12in 8-9/16x6x7-7/
	  	4165 EA	  	P3442-1	  	 Shpr,12in 8-9/16x6x7-7/
	  	4165 EA

  

					
		 	-22-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 APPENDIX E 

PRODUCT PRICES 
 Initial Purchase Prices 
  

							
	 Item Code
	  	 Item Description
	  	Price Per Unit	 
			
	 9000108
	  	 Gynazole -1® 2% Cream
	  	 	[***	] 
	 9000127
	  	 Gynazole -1® 2% Cream Sample
	  	 	[***	] 
	 9012408
	  	 Clindesse®
	  	 	[***	] 
	 9012427
	  	 Clindesse® Sample
	  	 	[***	] 

  

					
		 	-23-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 Purchase Price Calculation Principles 

See attached. 

[***] 

  

					
		 	-24-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

 APPENDIX F 

TECHNOLOGY TRANSFER PLAN 
 Clindesse 
  

	1.	Section 1 - QbD 

  

	 	1.1.	CDP00018C – Critical Quality Attributes/Critical Processing Parameters Assessment for Clindamycin Phosphate Vaginal Cream, 2% (Clindesse) 

 

	 	1.2.	CDP000018C.A1 – Addendum to Critical Quality Attributes/Critical Processing Parameters for Clindamycin Phosphate Vaginal Cream, 2% (Clindesse)

  

	2.	Protocols 

  

	 	2.1.	CDP000018C.1 – Experimental Protocol and Sampling/Testing Plan for Clindamycin Phosphate Vaginal Cream, 2.0% 

 

	 	2.2.	CDP000018C.2 – Experimental Protocol and Sampling/Testing Plan for Clindamycin Phosphate Vagina. Cream, 2.0% 

 

	 	2.3.	CDP000018C.3 - Experimental Protocol and Sampling/Testing Plan for Clindamycin Phosphate Vagina. Cream, 2.0% 

 

	 	2.4.	CDP000018C.4 – Protocol an Sampling/Testing Plan for the Verification of Clindamycin Phosphate Vaginal Cream, 2.0% 

 

	 	2.5.	CDP000018C.5 –Experimental Protocol and Sampling/Testing Plan for the Study of Viscosity vs. Time Clindamycin Phosphate Vaginal Cream, 2.0%

  

	 	2.6.	CDP000018C.7 – Clindesse Practice Batch for Operations Packaging Training 

 

	 	2.7.	CDP000018C.8 – Experimental Protocol and Sampling/Testing Plan for Clindamycin Phosphate Vaginal Cream, 2% 

 

	 	2.8.	CDP000018C.9 – Clindesse CAPA Demonstration Batch for Operations and Westport Plant QA Packaging and Line Clearance Training 

 

	3.	Reports 

  

	 	3.1.	CDR000018C.1 – Experimental Protocol Report for Clindamycin Phosphate Vaginal Cream, 2.0% Lot Number: DR205-61, DR205-70, DR222-03, R604-007 and DR205-70A,
DR222-03A Product Code Number 6912400C and 6912408C Evaluation of the Manufacturing and Packaging Processes 

  

	 	3.2.	CDR000018C.4 – Verification Protocol Report for: Clindamycin Phosphate Vaginal Cream, 2.0%, Lot Number R604-009 and R604-009A, Product Code Number 6912400 and
6912408 Evaluation of the Manufacturing and Packaging Processes 

  

	 	3.3.	CDR000018C.5 – Experimental Protocol Report for the Study of Viscosity vs. Time Clindamycin Phosphate Vaginal Cream, 2.0% (Clindesse) 

 

	 	3.4.	CDR000018C.6 – Technology Transfer Summary Report 

  

	 	3.5.	CDR000018C.6A1 – Technology Transfer Summary Report 

  

	 	3.6.	CDR000018C.6A2 – Addendum to the Technology Transfer Summary Report 

  

					
		 	-25-	 	

	 	3.7.	CDR000018C.8 – Experimental Protocol Report for: Clindamycin Phosphate Vaginal Cream, 2.0% Lot Number R604-012, Product Code Number: 6912400 Gynazole-1

  

	1.	Section 1 – QbD 

  

	 	1.1.	CDP000018B – Critical Quality Attributes/Critical Processing Parameters Assessment for Butoconazole Nitrate Cream, 2% w/w, (Gynazole-1) 

 

	2.	Section 2 – Protocols 

  

	 	2.1.	CDP000018B.1 – Experimental Protocol and Sampling/Testing Plan for Butoconazole Nitrate Cream, 2.0% w/w 

 

	 	2.2.	CDP000018B.1R1 – Revision to the Experimental Protocol and Sampling/Testing Plan for Butoconazole Nitrate Cream, 2.0% w/w 

 

	 	2.3.	CDP000018B.2 – Experimental Protocol and Sampling/Testing Plan for the Study of Viscosity vs. Time for Butoconazole Nitrate Cream, 2.0% w/w

  

	 	2.4.	CDP000018B.3 – Experimental Protocol and Sampling/Testing Plan for Butoconazole Nitrate Cream, 2.0% 

 

	 	2.5	CDP000018B.4 – Verification Protocol and Sampling/Testing Plan for Butoconazole Nitrate Cream, 2% w/w 

 

	 	2.6	CDP000018B.5 – Experimental Protocol and Sampling/Testing Plan for the Study of Viscosity vs. Time Butoconazole Nitrate Cream, 2.0% w/w 

 

	3.	Reports 

  

	 	3.1	CDR000018B.1 – Experimental Protocol Report for: Butoconazole Nitrate Cream, 2.0% w/w Lot Number DR205-62, DR-205-69, R604-006 and DR205-62A, DR205-69A Product
Code Number: 6900100B and 6900108A Evaluation of the Manufacturing and Packaging Processes. 

  

	 	3.2	CDR000018B.4 – Verification Protocol Report for Butoconazole Nitrate Cream, 2.0% w/w (Gynazole-1), Lot Number: R604-010 and R604-010A, Product Codes: 6900100B and
6900108 Evaluation of the Manufacturing and Packaging Processes 

  

	 	3.3	CDR000018B.4A1 – Addendum to the Verification Protocol Report for: Butoconazole Nitrate Cream, 2.0% w/w (Gynazole-1), Lot Number: R604-010 and R604-010A, Product
Codes: 6900100B and 6900108, Evaluation of the Manufacturing and Packaging Process 

  

	 	3.4	CDR000018B.5 – Experimental Protocol Report for the Study of Viscosity vs. Time Butoconazole Nitrate Cream, 2.0% (Gynazole), Lot Number: R604-010, Product Code
6900100B 

  

	 	3.5	CDR000018B.6 – Technology Transfer Summary Report Butoconazole Nitrate Cream, 2.0% w/w (Gynazole-1) Product Code Number: 6900100B and 6900108, Evaluation of
Manufacturing and Packaging Processes 

  

					
		 	-26-	 	

	 	3.6	CDR000018B.6A1 – Addendum to the Technology Transfer Summary Report Butoconazole Nitrate Cream, 2.0% w/w (Gynazole-1) Product Code Number: 6900100B and 6900108
Evaluation of the Manufacturing and Packaging Process 

  

					
		 	-27-	 	

 APPENDIX G 

TECHNICAL SUPPORT TERM SHEET 
  

					
	 Section
	 	  	  	 Comments

			
	I. DEFINED TERMS	 	•	  	Technical Support-full validation and stability of PRODUCT(s) and approval by US FDA
			
		 	•	  	Equipment-set forth in appendix A of Supply Agreement-“Customer Owned Equipment”
			
		 	•	  	Party(ies)-shall pertain solely to KV and SUPPLIER
			
		 	•	  	Timeline-Appendix H of the Supply Agreement
			
		 	•	  	Supply Agreement-that certain Supply Agreement, dated as of August     , 2011, by and between SUPPLIER and KV, which governs the actions and
responsibilities of the Parties with respect to the commercial manufacture and supply of the PRODUCT(s), and to which this Technical Support Term Sheet is an appendix.
			
		 	•	  	Purchase Price-means the purchase price for Product, as determined by SUPPLIER and agreed to by KV, calculated as the costs directly associated to Product materials
provided under Appendix D of the Supply Agreement, product testing and stability costs, direct and indirect labor and applicable overhead (direct and indirect) assigned to the Product based on facility utilization plus [***] percent
([***]%).
			
		 	•	  	Other Capitalized Terms-to the extent not otherwise defined in this Technical Support Term Sheet shall have the respective meanings ascribed to them in the Supply
Agreement.
			
	II. PRODUCT(S)	 	•	  	Gynazole-1®-butoconazole nitrate
2% intravaginal cream product
			
		 	•	  	Clindesse®-clindamycin phosphate
2% intravaginal cream product
			
	III. MATERIAL SUPPLY	 	•	  	At KV’s cost, KV to provide SUPPLIER with necessary materials as provided under Appendix C of the Supply Agreement to complete Technical Support of the PRODUCTS, to
include:
			
		 		  	 •      API

 

•      Raw Materials as required

 

•      Applicators and Tips

 

•      Pre-printed Packaging Materials

			
	IV. EQUIPMENT	 	•	  	KV to provide SUPPLIER full use of the Equipment necessary to manufacture the PRODUCTS
			
		 	•	  	SUPPLIER shall not use the Equipment for the manufacture of any other Product nor for any other Party.
			
	V. TIMELINE	 	•	  	Timeline representing KV’s expectation of time and events under commercially reasonable conditions is set forth in Appendix H of the Supply Agreement and remains contingent
upon the outcome of the active investigation.

  

					
		 	-28-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

					
		 	•	  	In the event the active investigation at the time of execution of the Supply Agreement reveals a need to alter the Timeline, the parties will meet in good faith to agree on an
appropriate amendment to the Timeline as contained in Appendix H of the Supply Agreement.
			
		 	•	  	SUPPLIER agrees to use commercially reasonable efforts to ensure the proper resources in terms of monies and personnel are dedicated to provide the Technical Support for the
development of the PRODUCTS in a manner that aligns with the Timeline, if possible.
			
		 	•	  	KV agrees to use commercially reasonable efforts to ensure the proper resources in terms of monies and personnel are dedicated to the development of the PRODUCTS in a manner that
aligns with the Timeline.
			
		 	•	  	To the extent commercially practicable, SUPPLIER shall use those Hired Employees (as defined in the APA) who were involved in the production of the Products prior to the Effective
Date in corresponding roles for SUPPLIER in the performance of its obligations under this Agreement.
			
		 	•	  	In the event that there are significant deviations from the Timeline, the Parties shall further discuss and meet in good faith to bring full resolution to the Timeline in a manner
that is agreed to in writing between the Parties with a target goal of achieving a successful development of the PRODUCTS in the most expeditious manner.
			
		 	•	  	In the event that one or both of the PRODUCTS fail to achieve FDA approval to return to market after the initial development phase set forth in the Timeline, the Parties shall
further discuss and meet in good faith to bring full resolution to the Timeline in a manner that is agreed to in writing between the Parties with a target goal of achieving a successful launch of the PRODUCTS in the most expeditious
manner.
			
	VI. MILESTONES	 	•	  	 On a per PRODUCT basis, KV will pay to SUPPLIER the following:

 

•         Purchase Price (For the avoidance of doubt, the
Parties agree that any validation batches of Clindesse produced by KV prior to the date of the Supply Agreement shall remain the property of KV and shall not be considered “Product” for which payment of the Purchase Price is
due)
  

•         $[***]USD for the successful approval to return to
market by the US FDA per PRODUCT
  

•         $[***]USD for the supply of [***]% of commercial
supply forecast per Product to KV by SUPPLIER in accordance with all relevant laws and cGMP for [***], beginning with KV’s first shipment into interstate commerce

  

					
		 	-29-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

					
	VII. MISCELLANEOUS	 	•	  	Parties agree to use good faith efforts and to cooperate with Lachman in all efforts related to the development of the PRODUCTS
			
		 	•	  	KV to receive directly from and pay for all invoices (without mark-up of any kind from SUPPLIER) for services of compliance and regulatory consultants (including without limitation
Lachman Consultants and Compliance) related to services and FDA audit costs in direct support of the PRODUCT certification
			
		 	•	  	KV to provide SUPPLIER with all necessary development and method validation documentation developed to date and that which would be necessary for the full validation of the
PRODUCTS. KV will be available to provide support and oversight to SUPPLIER in the Technical Support of the PRODUCTS, KV will have a representative in the plant responsible for overseeing activities of SUPPLIER on behalf of KV as
necessary.
			
		 	•	  	SUPPLIER agrees to conduct all Technical Support efforts in a manner that is in full compliance with all government and regulatory standards, the Consent Decree, and in accordance
with cGMP standards
			
		 	•	  	Upon KV’s prior written approval, any out of pocket costs specifically related to the Technical Support will be paid for by KV upon presentation of supporting documentation by
SUPPLIER.
			
	VIII. COMPLETION	 	•	  	This Technical Support Term Sheet will come to completion upon the successful Technical Support of each of the PRODUCT(S)
			
		 	•	  	Upon US FDA approval of the PRODUCT, the Parties will refer solely to the Supply Agreement to govern responsibilities and actions of the Parties for that Product
			
		 	•	  	During the term of this Technical Support Term Sheet, KV shall pay SUPPLIER all SUPPLIER costs, including SUPPLIER paid Product, Product testing and stability costs, direct and
indirect labor and applicable overhead (direct and indirect) assigned to the Product based on facilities utilization plus [***] percent ([***]%). SUPPLIER shall invoice customer monthly for such amounts.
			
	IX. FOR ELIMINATION OF DOUBT	 	•	  	SUPPLIER accepts no responsibility for any development work necessary to obtain US FDA approval (e.g. clinical, updated methods etc.) except where required to maintain compliance
with current or mandated regulatory revisions. SUPPLIER will reasonably cooperate with KV in connection any supporting development work being done by KV.
			
		 	•	  	SUPPLIER will accept no responsibility for damages due to the lack of timely activities associated with obtaining US FDA approval to return to market provided SUPPLIER resources the
Timeline with reasonable effort per above.

  

					
		 	-30-	 	*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

					
		 	 •
	  	SUPPLIER has no knowledge or experience with KV PRODUCTS and accepts no responsibility for the commercial success or failure of said PRODUCTS.
			
		 	 •
	  	The terms of this Technical Support Term Sheet shall be in addition to and otherwise subject to the terms and conditions agreed to between the Parties in the Supply Agreement,
including the limitations of liability set forth therein.

  

					
		 	-31-	 	

 APPENDIX H 

TECHNICAL SUPPORT TIMELINE 
 See attached. 
 [***] 

*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect
to the omitted portions. 

  

					
		 	-32-Exhibit 10.2

 Exhibit 10.2 
 Space Above Line Reserved for Recorder’s Use 
  

			
	 1.      Title of Document:
	  	Note, Deed of Trust, Leasehold Deed of Trust, Security Agreement and Fixture Filing, and Other Loan Documents Modification and Spreader Agreement
		
	 2.      Date of Document:
	  	                    , 2011
		
	 3.      Grantor/Borrower:
	  	 MECW, LLC, a Missouri limited liability company
 c/o The Corporation Trust Company
 Corporation Trust Center

One Corporate Woods Drive
 Bridgeton, Missouri
63044

		
	 4.      Grantee/Lender:
	  	 U.S. Bank, National Association, as Trustee for the Registered Holders of J.P. Morgan Chase Commercial Mortgage Securities Corp.,
Commercial Mortgage Pass-Through certificates, Series 2006-LDP7
 209 South LaSalle Street, Suite 300

Chicago, Illinois 60604

		
	 5.      Legal description:
	  	See Exhibits A-1 and A-2 attached.
		
	 6.      Reference to Book& Page:
	  	Document No. 2006032400757 in Book 17103, Page 4108 of the St. Louis County, Missouri Recorder of Deeds

			
	After recording, return to:	 	
		 
	 Bilzin Sumberg Baena

Price & Axelrod LLP
	 	
	 200 South Biscayne Boulevard, Suite 2500
 Miami, Florida 33131-5340
	 	
	Attn: Post-Closing Department	 	

  
  

(Space Above For Recorder’s Use Only) 
 NOTE, DEED OF TRUST, LEASEHOLD DEED OF TRUST, SECURITY 

AGREEMENT AND FIXTURE FILING, AND OTHER LOAN 
 DOCUMENTS MODIFICATION AND SPREADER AGREEMENT 
 (JPMCC
2006-LDP7; Loan No. 991077168) 
 THIS NOTE, DEED OF TRUST, LEASEHOLD DEED OF TRUST, SECURITY AGREEMENT, AND
FIXTURE FILING, AND OTHER LOAN DOCUMENTS MODIFICATION AND SPREADER AGREEMENT (the “Agreement”) is executed this      day of
                    , 2011 (“Execution Date”), to be effective as of the      day of
                    , 2011 (“Effective Date”), and is entered into by and between U.S. BANK, NATIONAL ASSOCIATION, AS TRUSTEE FOR
THE REGISTERED HOLDERS OF J.P. MORGAN CHASE COMMERCIAL MORTGAGE SECURITIES CORP., COMMERCIAL MORTGAGE PASS-THROUGH CERTIFICATES, SERIES 2006-LDP7 (“Lender”), having an address at 209 South LaSalle Street, Suite 300, Chicago,
Illinois, 60604, Re: JPMCC 2006-LDP7; Loan No. 991077168; and MECW, LLC, a Delaware limited liability company (“Borrower”), having an address at One Corporate Woods Dr., Bridgeton, MO. 63044. 

PRELIMINARY STATEMENT 
 A. On or about March, 23, 2006, LaSalle Bank National Association, a national banking association (“Original Lender”) made a loan (“Loan”) to Borrower with respect to
(i) a leasehold estate on premises commonly known as “Metro 1, Metro 2 and Corporate Woods (EC4)” located in the cities of Maryland Heights (as to Metro 1 and Metro 2) and Bridgeton (as to Corporate Woods EC4), all located in St.
Louis County, Missouri (the “State”) and more particularly described on the attached Exhibit A-1 (the “Spreader Property”) and (ii) a fee estate on premises commonly known as “Corporate
Exchange” located in the city of Bridgeton, in St. Louis County, Missouri and more particularly described on the attached Exhibit A-2 (the “Original Mortgaged Property”) which such Loan is evidenced or secured by, among
others, the documents described on the attached Exhibit B (collectively referred to as “Loan Documents”). 

  
 2 

 B. All of Original Lender’s right, title and interest in and to the Loan has been
transferred and assigned to Lender. 
 C. The Spreader Property is subject to a Lease Agreement dated as of December 1,
2005 (the “Chapter 100 County Lease”) by and between St. Louis County, Missouri (“St. Louis County”), as landlord, and K-V Pharmaceutical Company, a Delaware corporation (“Borrower’s Sole
Member”), as tenant. The Borrower’s Sole Member, as tenant under the Chapter 100 County Lease, subsequently assigned its leasehold interest in the Spreader Property to Borrower pursuant to that certain Partial Assignment and Assumption
Agreement dated as of March 23, 2006 (the “Assignment”). Borrower, as sublandlord, subsequently subleased the Spreader Property to Borrower’s Sole Member, as subtenant, by virtue of certain subleases for the (i) Metro
1 and Metro 2 properties (the “Metro Court Sublease”) and (ii) Corporate Woods (EC4) property (the “Corporate Woods Sublease” and together with the Metro Court Sublease, the “Subleases”).

 D. The Original Mortgaged Property is subject to a Lease Agreement dated as of March     , 2006 (the
“3100 Corporate Exchange Lease”) by and between Borrower, as landlord, and Borrower’s Sole Member, as tenant. 
 E. As part of the unwinding of the Chapter 100 County Lease, St. Louis County will convey to Borrower fee simple title to the Spreader Property by Special Warranty Deed to be recorded in the Records (as
defined in Exhibit B hereof). 
 F. The Original Mortgaged Property together with the Spreader Property shall hereinafter
mean and refer to the “Amended and Restated Mortgaged Property” and more particularly described on the attached Exhibit A-3. 
 G. Borrower has requested Lender to, among other things, (i) waive certain financial reporting requirements under the Loan Documents; (ii) waive the minimum net worth requirements under the Loan
Documents for a set period of time as set forth in this Agreement; (iii) release Particle Dynamics, Inc., a New York corporation (“PDI”) as a guarantor under the Guaranty (as defined in Exhibit B) and Environmental
Indemnity (as defined in Exhibit B); (iv) release ETHEX Corporation, a Missouri corporation (“ETHEX”) as a guarantor under the Guaranty and Environmental Indemnity; (v) consent to termination of the Chapter 100
County Lease; (vi) consent to amendment and restatement of the Subleases to convert the Subleases into direct leases between Borrower, as landlord, and Borrower’s Sole Member, as tenant; (vii) consent to amendment of the 3100
Corporate Exchange Lease; (viii) spread the lien of the Security Instrument to encumber the Borrower’s fee interest in the Spreader Property; (ix) change the legal description to the land encumbered by the Security Instrument to the
legal description of the Amended and Restated Mortgaged Property; (x) consent to cancellation of the Bonds and waive notice of the redemption of the Bonds; and (xi) consent to the sublease of a portion of the Corporate Woods (EC4) property
to Zynesher Pharmaceuticals (USA) LLC, a Missouri limited liability company (collectively, the “Requested Actions”); 
 H. PDI and ETHEX shall individually and collectively be referred to herein as the “Released Guarantor.” Borrower’s Sole Member (as hereinafter defined) and Ther-Rx (as hereinafter
defined) shall individually and collectively be referred to herein as “Current Guarantor.” 

  
 3 

 I. Lender and Borrower have agreed to modify the Loan Documents consistent with the
Requested Actions, on the terms and conditions set forth in this Agreement. 
 In consideration of $10.00 paid by each of the
Parties (as hereinafter defined) to the other, the mutual covenants set forth below, and other good and valuable consideration, receipt and sufficiency of which are acknowledged, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS 
 The terms set forth below have the meaning ascribed to
them for purposes of this Agreement. Other capitalized terms contained in this Agreement shall have the meanings assigned to them herein. Any capitalized terms utilized in this Agreement and not defined in this Agreement shall have the meanings set
forth in the Loan Documents. 
 1.1 “Collateral” means any and all real and personal property described in any
of the Loan Documents as security for Borrower’s obligations under the Loan, including, without limitation, the Property. 

1.2 “Debtor Proceeding” means any proceeding for relief, protection, reorganization, liquidation, dissolution or similar
relief for debtors under any present or future local, state, federal or other insolvency law or laws providing relief for debtors. 
 1.3 “Indebtedness” means the total amount described in Section 2.3(b) plus all other amounts that may subsequently be due from Borrower to Lender under the Loan Documents, this
Agreement, and at law or in equity, including advances made by any Servicer, together with any interest thereon. 
 1.4
“Party” means any, and “Parties” means all, of the signatories to this Agreement. 
 1.5
“Servicer” means Berkadia Commercial Mortgage, LLC and LNR Partners, LLC, and any other party appointed as servicer of the Loan. 

  
 4 

 ARTICLE 2 

ACKNOWLEDGMENTS, WARRANTIES AND REPRESENTATIONS 
 Borrower acknowledges, warrants, represents and agrees as follows as of the Execution Date and the Effective Date: 
 2.1 Authority of Borrower. 
 (a) Borrower. Borrower is a duly
organized and validly existing limited liability company in good standing under the laws of the State of Delaware and is qualified to transact business in the State of Missouri. Borrower Sole Member is the sole member of Borrower. Borrower’s
Sole Member, acting alone without the joinder of any other members or managers of Borrower or any other party, has the power and authority to execute and deliver this Agreement and any and all documents executed in connection herewith (collectively
referred to herein as the “Modification Documents”) on behalf of and to duly bind Borrower under this Agreement and the Modification Documents. The execution and delivery of, and performance under, this Agreement and the
Modification Documents by Borrower has been duly and properly authorized pursuant to all requisite company action of Borrower and does not and will not (x) violate any provision of any law, rule, regulation, order, writ, judgment, injunction,
decree, determination or award presently in effect having applicability to Borrower or Borrower’s certificate of formation or articles of organization, limited liability company or operating agreement or any other organizational document of
Borrower or (y) result in a breach of or constitute or cause a default under any indenture, agreement, lease or instrument to which Borrower is a party or by which the Property may be bound or affected. 

(b) Borrower’s Sole Member. Borrower’s Sole Member is a duly organized, validly existing corporation organized under the
laws of the State of Delaware. Gregory J. Divis (“Authorized Signatory”) is the President and Chief Executive Officer of Borrower’s Sole Member. Authorized Signatory, acting alone without the joinder of any officer, director or
shareholder of Borrower’s Sole Member or any other party, has the full power and authority to execute this Agreement and the Modification Documents on behalf of Borrower’s Sole Member and Borrower and to duly bind Borrower’s Sole
Member and Borrower under this Agreement and the Modification Documents. The execution and delivery of this Agreement and the Modification Documents and the performance of the obligations thereunder by Borrower’s Sole Member does not and will
not (i) conflict with, or result in a breach or violation of any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to Borrower’s Sole Member
or the articles of incorporation or the bylaws of Borrower’s Sole Member, or (ii) result in a breach or constitute or cause a default under any indenture, agreement, lease or instrument to which Borrower’s Sole Member is a party or by
which it or the Borrower’s Sole Member is bound. 
 2.2 Status of Loan. 

(a) Loan Documents. The Loan Documents constitute valid and legally binding obligations of Borrower and are enforceable against
Borrower and the Amended and Restated Mortgaged Property in accordance with their terms. There are no modifications, verbal or written, to the Loan Documents other than those, if any, described on the attached Exhibit B. Borrower has waived
or released, or by its execution of this Agreement, waives and releases all defenses, setoffs, claims, counterclaims or causes of action of any kind or nature whatsoever against Lender, Servicer and Lender’s and Servicer’s predecessors in
interest, and all of the respective past, present and future officers, directors, employees, agents, 

  
 5 

 
servicers, attorneys, representatives, participants, heirs, successors and assigns of Lender, Servicer and Lender’s and Servicer’s predecessors in interest (collectively,
“Lender Parties”) with respect to (i) the Loan, (ii) the Loan Documents, (iii) the Indebtedness, or (iv) the Property. 
 (b) Indebtedness. As of July 29, 2011, the outstanding principal balance of the Loan is $32,223,169.27 (the “Principal”). The term “Indebtedness” also
includes any and all other interest, advances, debts, obligations and liabilities of Borrower under the Loan Documents or this Agreement, whether voluntary or involuntary, however arising, including, without limitation, advances made by a Servicer
together with any interest thereon, and administrative charges. 
 (c) Assignment of Leases. The Assignment of Leases
described in Exhibit B constitutes an absolute, unconditional, current, assignments of rents, issues and profits from the Property, and all actions, if any, required to be taken by Lender to perfect its rights to collect such rents, issues
and profits have been duly and properly taken by Lender. It is the intent of the Parties that Lender’s security interest pursuant to the Assignment of Leases remains and shall at all times remain perfected. 

(d) Representations in Security Instrument and Other Loan Documents. Except as disclosed by Borrower in Borrower’s publicly
filed financial statements or otherwise disclosed in writing by Borrower to Lender, the representations and warranties contained in the Security Instrument described in Exhibit B and the other Loan Documents are true and correct as of the
Execution Date and the Effective Date as if made on such dates. 
 (e) Borrower and Borrower’s Sole Member, as applicable,
submitted its SEC Form 10-Q for the quarter ending December 31, 2010, prior to March 31, 2011. 
 (f) Borrower
delivered and caused Guarantor to deliver to Lender, the audited balance sheets, statements of income and expenses and statements of cash flows, and other financial information as more particularly required under Section 10 of the Security
Instrument prior to the Effective Date hereof. 
 (g) Borrower and Borrower’s Sole Member, as applicable, are current with
their SEC filings, and submitted their SEC Form 10-K for the quarter ending March 31, 2011, prior to June 15, 2011. 

2.3 No Bankruptcy Intent. None of Borrower, Borrower’s Sole Member or Current Guarantor (collectively,
“Borrower Parties”) have the intent to (a) file a voluntary petition with any bankruptcy court of competent jurisdiction or be the subject of any petition under Title 11 of the U.S. Code, as amended (the “Bankruptcy
Code”); (b) be the subject of any order for relief issued under the Bankruptcy Code; (c) file or be the subject of any petition seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution, or
similar relief under any present or future federal or state act or law relating to bankruptcy, insolvency, or other relief for debtors; (d) have sought or consented to or acquiesced in the appointment of any trustee, receiver, conservator,
liquidator or assignee for the benefit of creditors; or (e) be the subject of any order, judgment, or decree entered by any court of competent jurisdiction 

  
 6 

 
approving a petition filed against such party in connection with any Debtor Proceeding. Borrower acknowledges that the filing of any petition or the seeking of any relief in a Debtor Proceeding
by any of Borrower Parties, whether directly or indirectly, would be in bad faith and solely for purposes of delaying, inhibiting or otherwise impeding the exercise by Lender of Lender’s rights and remedies against Borrower and the Property
pursuant to the Loan Documents or at law. 
 2.4 Financial Statements. The financial statements of the Borrower
Parties previously delivered by Borrower to Lender (the “Financial Statements”) are true, complete and accurate in every material respect and accurately represent, respectively, the financial condition of the Borrower Parties and
the income and expenses related to the Property, as of the date thereof. The Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the period involved. There has
not been any material adverse change between the dates of the Financial Statements and the date of this Agreement. Borrower acknowledges that the Financial Statements have been provided to Lender to induce Lender to enter into this Agreement and are
being relied upon by Lender for such purposes. 
 2.5 Title to Property and Legal Proceedings. There are no:
(a) pending or threatened suits, judgments, arbitration proceedings, administrative claims, executions or other legal or equitable actions or proceedings against Borrower or the Property, (b) liens, mortgages (other than the Security
Instrument), claims of lien or other encumbrances, except for the exceptions set forth on Schedule B of Lender’s mortgagee title insurance policy (the “Permitted Encumbrances”), against the Property which could reasonably have
a material adverse effect on Borrower or the Property, or (c) pending or to Borrower’s knowledge, threatened condemnation proceedings or annexation proceedings affecting the Property, nor any agreements to convey any portion of the
Property, or any rights thereto to any person or entity not disclosed in this Agreement, including, without limitation, any government or governmental agency. 
 2.6 Status of the Property. 
 (a) Compliance with Laws.
Borrower has not received any written notice from any governmental entity claiming that Borrower or the Property is not presently in compliance with any laws, ordinances, rules and regulations bearing upon the use and operation of the Property,
including, without limitation, any notice relating to building, zoning, environmental, life safety, wetlands, or handicapped accessibility laws, codes or regulations. All permits, licenses or other evidences of authority to use and operate the
Property as it is presently being operated and as contemplated by the Loan Documents are current, valid and in full force and effect. 
 (b) Taxes. All real estate taxes, personal property taxes, sales taxes and similar liabilities, assessments or expenses currently due and payable with respect to the Property have been fully and
timely paid. 
 (c) Hazardous Wastes. To the Borrower’s knowledge, no portion of the Property has been used in the
past or will in the future be used for or in connection with the handling, generation, use, storage or disposal of Hazardous Substances. No Hazardous 

  
 7 

 
Substances are located or will be located on or under or used or stored on or generated from any portion of the Property. No above ground or underground storage tanks are have in the past been or
will in the future be located on or below the surface of any portion of the Property. No portion of the Property is included on any governmental agency’s list of sites on or under which Hazardous Substances may be located, used, stored or
generated or with respect to which remedial action may be necessary. All federal, state and local permits concerning or related to environmental protection and regulation at the Property, if any, have been secured, are current and will continue to
remain current, and Borrower is and will remain in compliance with the terms thereof. There are no past or current releases and will be no future releases of Hazardous Substances on, over, at, from, into or onto the Property; and Borrower is not
aware of any environmental condition, situation or incident on, at, or concerning the Property that could give rise to an action or to liability for environmental matters under any law, rule, ordinance or common law theory. 

2.7 Continuity of Representations. The representations and warranties contained in this Agreement are true and correct in
all material respects as of the Effective Date and the Execution Date and will survive the termination of this Agreement by the passage of time or otherwise. 
 ARTICLE 3 
 COVENANTS OF BORROWER 

Borrower covenants and agrees with Lender that: 
 3.1 Compliance with Loan Documents. To the extent not inconsistent with the terms of this Agreement, Borrower agrees to comply with and be bound by all the terms, covenants and agreements,
conditions and provisions set forth in the Loan Documents. 
 3.2 Notice of Proceedings. Borrower shall notify
Lender in writing, promptly after acquiring knowledge, either directly or through any agent, of the institution of any suit, administrative proceeding, adversary proceeding or other legal proceedings which may materially affect the operations,
financial condition, title or business of the Property or the transactions contemplated by this Agreement. 
 3.3 Release
and Covenant Not To Sue. In consideration of Lender’s agreement to the terms of this Agreement, Borrower Parties and Released Guarantor, on behalf of themselves and their partners and members and each of their respective heirs,
successors and assigns, remise, release, acquit, satisfy and forever discharge Lender Parties, from any and all manner of debts, accountings, bonds, warranties, representations, covenants, promises, contracts, controversies, agreements, liabilities,
obligations, expenses, damages, judgments, executions, actions, claims, demands and causes of action of any nature whatsoever, at law or in equity, known or unknown, either now accrued or subsequently maturing, which any of them now has or hereafter
can, shall or may have by reason of any matter, cause or thing, from the beginning of the world to and including the Execution Date, including, without limitation, matters arising out of or relating to (a) the Loan, (b) the Loan Documents,
(c) the Indebtedness, (d) the Property, and (e) any other agreement or transaction between (i) the Borrower Parties and (ii) any of Lender Parties relating to the Loan. Borrower Parties and Released Guarantor, on behalf of
themselves 

  
 8 

 
and their partners and members and each of their respective heirs, successors and assigns, covenant and agree never to institute or cause to be instituted or continue prosecution of any suit or
other form of action or proceeding of any kind or nature whatsoever against any of Lender Parties by reason of or in connection with any of the foregoing matters, claims or causes of action. 

3.4 Hazardous Wastes. Borrower agrees to promptly deliver to Lender any notices related to any of the matters described in
Section 2.6(c) of this Agreement and to indemnify and save Lender harmless from any and all actions, claims, damages, liabilities and fees, punitive damages and penalties, directly or indirectly arising out of the generation, storage or
disposal of hazardous materials, including, without limitation, the cost of any required or necessary repair, clean-up or detoxification. The indemnity provisions of this Section shall survive any satisfaction of the Loan or a release or
reconveyance of the Security Instrument. 
 3.5 Bankruptcy. In the event that any of the Borrower Parties shall
take any action constituting a Debtor Proceeding, and such action causes Lender to seek necessary or appropriate relief: (i) Lender shall thereupon be entitled to and Borrower irrevocably consents to (a) the relief from any automatic stay
imposed by Section 362 of Bankruptcy Code, or otherwise, on or against the exercise of the rights and remedies otherwise available to Lender as provided in this Agreement with respect to the Property and as otherwise provided by law, and
Borrower hereby irrevocably waives any right to object to such relief, and acknowledges that no reorganization in bankruptcy is feasible and (b) an order from the bankruptcy court prohibiting Borrower’s use of all “cash
collateral” (as defined in Section 363 of the Bankruptcy Code); (ii) Borrower waives its exclusive right pursuant to Section 1121(b) of the Bankruptcy Code to file a plan of reorganization and irrevocably agrees and consents that
Lender may file a plan immediately upon the entry of an order for relief if an involuntary petition is filed against Borrower or upon the filing of a voluntary petition by Borrower; (iii) in the event that Lender shall move pursuant to
Section 1121(d) of the Bankruptcy Code for an order reducing the 120 day exclusive period, Borrower shall not object to any such motion, and (iv) Borrower waives any rights it may have pursuant to Section 108(b) of the Bankruptcy
Code. The provisions of this Section shall survive the termination of this Agreement. 
 3.6 Modification Fee.
Prior to the Execution Date hereof, Borrower has paid Lender a non-refundable modification fee in the total amount of $25,000.00 (“Modification Fee”). Borrower acknowledges and agrees that the Modification Fee shall be deemed earned
by Lender upon execution of this Agreement by Lender, notwithstanding the date(s) upon which Borrower paid the Modification Fee and the date upon which Borrower ultimately pays the Indebtedness, and shall not be applied by Lender at any time to
reduce the Indebtedness. 
 3.7 Payment of Legal Retainer, Transaction Costs and Expenses. Borrower shall pay all
costs incurred in connection with the preparation, negotiation, execution and recording of this Agreement and related transactions, including, without limitation (the “Transaction Expenses”): (a) the reasonable legal fees and
disbursements of Lender’s general counsel, Bilzin Sumberg Baena Price & Axelrod LLP, and Lender’s local counsel, if applicable; (b) all recording costs, taxes, documentary stamps and other charges, costs and fees due upon the
recording of assignments of the Loan Documents to Lender, if not previously recorded, and upon the 

  
 9 

 
recording of this Agreement, if Lender elects to record same; (c) the costs of updating Lender’s policy of title insurance insuring the Security Instrument to a current date and
endorsing such policy (the “Title Endorsement”) to (i) change the effective date to the date of recording of this Agreement, if recorded; (ii) change the name of the insured to Lender; (iii) show no additional
exceptions to Schedule B of said title insurance policy except as approved by Lender in writing and (iv) provide such other coverage as may be requested by Lender; and (d) certificates of good standing issued by the applicable Secretary of
State for all Borrower Parties (the “Certificates of Good Standing”). The Transaction Expenses shall be paid by Borrower simultaneously with the execution of this Agreement. Borrower acknowledges and agrees that Lender shall not
apply any of the Transaction Expenses at any time to reduce the Indebtedness. The parties acknowledge and agree that prior to the Execution Date hereof Borrower paid to Lender a refundable fee in the total amount of $25,000.00, which refundable fee
shall be used for the Transaction Expenses payable by Borrower as set forth in this Section 3.7. 
 3.8 Additional
Documents. Simultaneously with the Execution Date, Borrower shall deliver or cause to be delivered to Lender the Title Endorsement, the Certificates of Good Standing and such affidavits, indemnities, certificates and legal opinions,
regarding among other things formation and authorization of Borrower Parties and enforceability of the Modification Documents, as may be requested by Lender. 
 3.9 Further Assurances. Borrower shall thereafter execute and deliver to Lender such agreements, instruments, documents, financing statements and other writings as may be reasonably
requested from time to time by Lender to perfect and to maintain the perfection of Lender’s security interest in and to the Property and to consummate the transactions contemplated by or in the Loan Documents and this Agreement. 

ARTICLE 4 
 SPREADER AND MODIFICATIONS 
 4.1 Consent of Lender.
Subject to the terms of this Agreement, Lender hereby consents to the Requested Actions. Borrower Parties agree that this Agreement shall not be deemed an agreement by Lender to consent to any other contemplated action relating to the Property, or a
consent to any secondary financing or secondary encumbrance on the Property. 
 4.2 Spreading of Lien. By
execution of this Agreement, Borrower hereby confirms and reaffirms the provisions of the Security Instrument and hereby mortgages, gives, grants, bargains, sells, alienates, enfeoffs, transfers, conveys, confirms warrants, pledges, assigns,
hypothecates and grants a security interest to Lender, its successors and assigns forever, all of Borrower’s right, title and interest in and to the Spreader Property, together with all property rights and interests related thereto and
encompassed within the definition of “Property” as contained in the Security Instrument. Lender and Borrower acknowledge and agree that the lien of the Security Instrument and, as applicable, of the other Loan Documents will
continue uninterrupted and in full force and effect with respect to the Mortgaged Property, and will, from and after the date of this Agreement, encumber Borrower’s right, title and interest in and to the Spreader Property as a first mortgage
lien. 

  
 10 

 4.3 Modifications. The Loan Documents are modified as follows: 

(a) Modifications to the Security Instrument. 
 (i) Section 3(c) of the Security Instrument shall be modified as follows: 

A. As a material inducement to Lender to consent to the Requested Actions, Borrower agrees that from and after the Effective Date, the
obligation of Borrower set forth in Section 3(c) of the Security Instrument to make the Replacement Reserve Monthly Payment shall be reinstated. 
 B. In the event that the Guarantors maintain a net worth of at least $250,000,000.00 as required by Section 3(c)(1) of the Security Instrument and Section 3.11 of the Guaranty, and provided that
there exists no Event of Default (or event with which notice or lapse of time or both could constitute an Event of Default) under the Loan Documents, Lender shall disburse the remainder of any of the Replacement Reserve to Borrower. 

(ii) Section 10 of the Security Instrument is modified as follows: Borrower shall be required to comply on a going forward basis,
with all financial reporting requirements under the Loan Documents as modified by this Agreement. 
 (iii) Section 56 of
the Security Instrument is hereby deleted in its entirety. 
 (b) Modifications to the Guaranty. Section 3.11
of the Guaranty is modified to provide that Lender will not enforce the minimum net worth requirement, as calculated under Section 3.11 of the Guaranty, until the financial quarter ending March 31, 2015 at which time Borrower’s Sole
Member shall be required to again be in compliance with the net worth requirements contained therein. 
 (c) Modifications
to the Loan Documents. 
 (i) All references in this Agreement, the Security Instrument and the other Loan Documents to
the term “Property” shall hereinafter mean and refer to collectively as the “Amended and Restated Mortgaged Property.” 
 (ii) All references in the Security Instrument and the other Loan Documents to the terms “Mortgage,” “Deed of Trust,” “Security Instrument,”
“Guaranty” or “Loan Documents” and “Obligations” shall hereafter mean and refer to the “Mortgage,” “Deed of Trust,” “Security Instrument,”
“Guaranty” or “Loan Documents” and “Obligations” as modified or affected by this Agreement. 
 (iii) All references in the Security Instrument and the other Loan Documents to the terms “Ground Lease,” “Ground Rents,” “Ground Lessor,”
“Ground Rent Escrow Subaccount,” and “Ground Rent Reserve” are hereby deleted. 

  
 11 

 4.4 Current Guarantor. As a condition to Lender’s execution of this
Agreement, Current Guarantor shall execute and deliver to Lender, simultaneously with the execution of this Agreement, the Joinder and Agreement of Current Guarantor attached hereto (the “Joinder”). 

4.5 Release of PDI and ETHEX. As a condition to Lender’s execution of this Agreement, Released Guarantor shall execute
and deliver to Lender, simultaneously with the execution of this Agreement, the Joinder by and Agreement of Released Guarantor attached hereto (the “Released Guarantor Joinder”). 

4.6 UCC Financing Statements. Borrower hereby grants and confirms unto Lender a first lien priority interest in all
Collateral to the maximum extent permitted by the Uniform Commercial Code, as may have been amended subsequent to the making of the Loan. Borrower hereby further consents to the filing of any financing statements or Uniform Commercial Code forms
required to be filed in the applicable states or any other filing office (collectively “Filings”) in order to perfect said interest and, notwithstanding anything contained in any of the Loan Documents to the contrary, in accordance
with the Uniform Commercial Code, as amended subsequent to the making of the Loan, said Filings may be made by Lender without the consent or signature of Borrower. 
 ARTICLE 5 
 DEFAULTS; REMEDIES 

5.1 Events of Default. Each of the following shall constitute an additional Event of Default (“Default”)
under the Loan Documents. The reference to Defaults contained in this Section shall not be deemed exclusive and shall not supersede all other Defaults or Events of Default contained in the Loan Documents. 

(a) Payments. If Borrower shall fail to pay any payment provided for in this Agreement when the same shall become due and after
the expiration of any applicable grace or cure period. 
 (b) Indebtedness. If Borrower shall fail to pay the entire
Indebtedness due under the terms of the Loan Documents and this Agreement. 
 (c) Misrepresentations. If any
representation or warranty of Borrower in this Agreement shall be proved to be untrue or inaccurate in any material respect when made. 
 (d) Breach of Other Covenants. If Borrower shall breach, default under or fail to fully and timely perform any of its covenants, agreements and obligations under this Agreement. 

5.2 Lender’s Rights upon Occurrence of Default. Upon the occurrence of a Default, Lender shall immediately be
entitled, without further notice to Borrower to exercise any or all of Lender’s rights and remedies under this Agreement, the Loan Documents, in equity and at law (all of such rights and remedies being cumulative), including, but not limited
to, demanding immediate payment of the entire Indebtedness and commencing foreclosure proceedings (“Foreclosure Proceedings”) against Borrower and the Property (whether commenced by judicial action or non-judicial power of sale, if
applicable. 

  
 12 

 5.3 Cooperation of Borrower upon Default. It is the express intent of Borrower
and Lender that, upon the occurrence of a Default, Lender shall be able to acquire possession of and title to the Property at the earliest possible date and otherwise commence and fully exercise, without interference by Borrower in any rights or
remedies given to Lender under this Agreement and the Loan Documents. In consideration of and as a material inducement to Lender to enter into this Agreement, Borrower agrees to waive and does hereby waive all defenses and agrees not to challenge in
any way the validity of any Foreclosure Proceedings related to the Property and/or the other Collateral or any other exercise by Lender of its rights and remedies under this Agreement, the Loan Documents, in equity or at law commenced from time to
time by Lender following the occurrence of a Default. In addition, upon the occurrence of a Default, Borrower shall not take any action of any kind or nature whatsoever, either directly or indirectly, to delay, oppose, impede, obstruct, hinder,
enjoin or otherwise interfere with, and Borrower will cooperate and comply with the exercise by Lender of any and all of Lender’s rights and remedies against Borrower or with respect to the Property and the other Collateral, or any other rights
or remedies of Lender with respect to the Loan, the Loan Documents, this Agreement, in equity and at law, including, without limitation, any actions by Lender to exercise the Assignment of Leases (whether or not involving the appointment of a
receiver) or to obtain title to the Property and the other Collateral by foreclosure or deed-in-lieu of foreclosure of the Security Instrument. 
 5.4 Conveyance Documents. Upon the occurrence of a Default, Borrower shall, upon request by Lender, execute and deliver such documents and instruments as Lender, Lender’s designee or
the title company insuring title to the Property may determine are necessary to issue to Lender or its designee an owner’s title insurance policy insuring the fee simple title to the Property, subject only to the Permitted Encumbrances, and to
convey to Lender or its designee at such sale all ownership and development rights with respect to the Property (including, without limitation, a special warranty deed or its equivalent, bill of sale, assignment and/or other conveyance documents
necessary to transfer, convey and assign all tangible and intangible, real and personal and mixed property used, useable or intended to be used in connection with the ownership, management and/or use of the Property, an assignment of all of
Borrower’s rights in and to the Permitted Encumbrances, and an assignment of all rights of Borrower to use any trademarks and logos for all or any portion of the Property). 

5.5 Property Materials. If a sheriff’s, clerk’s or trustee’s deed for the Property is issued to Lender or
its designee pursuant to a judicial or trustee’s sale, or if Lender acquires the Property by deed in lieu of foreclosure or otherwise, promptly upon request by Lender, Borrower shall deliver and/or pay to Lender, the following as to all or any
portion of the Property acquired by Lender provided same are in Borrower’s possession or control: (i) possession of the Property, (ii) the originals (or true and correct copies, if the originals are not available) of all guaranties
and warranties given with respect to all or any portion of the Property or any improvement located thereon which Borrower has in its possession, (iii) the originals (or true and correct copies, if the originals are not available) of all service
contracts and management agreements then in effect with respect to the Property, (iv) the originals (or true and correct copies, if the 

  
 13 

 
originals are not available) of all plans, specifications, working drawings and surveys of or relating to the Property or to the construction of the buildings and related improvements located
thereon, (v) the originals (or true and correct copies, if the originals are not available) of all governmental consents, approvals, licenses, permits, certificates of occupancy, zoning approvals, building permits and similar documents relating
to the Property, (vi) copies of all books and records in any way relating to the Property, (vii) the balance of any funds in any security deposit accounts and any and all other tenant security deposits, and any and all advance rentals or
similar fees, if any, (viii) the originals (or true and correct copies, if the originals are not available) of all termite or other inspection reports, bonds, warranties and guaranties relating to the Property, (ix) any and all income from
the Property received by or on behalf of Borrower and then being held by or on behalf of Borrower; (x) the originals (or true and correct copies, if the originals are not available) of all certificates, binders and policies of insurance
relating to the Property, (xi) the originals (or true and correct copies, if the originals are not available) of all contracts and agreements with contractors, architects, engineers, surveyors and others relating to all or any portion of the
Property, (xii) the originals (or true and correct copies, if the originals are not available) of all tenant leases and occupancy agreements affecting all or any portion of the Property, (xiii) all leasing and other files, books and
records with respect to all or any portion of the Property, and (xiv) any bankruptcy claims relating to any current or former tenant of the Property, duly assigned to Lender or its designee. 

5.6 Cooperation Covenants. The covenants and agreements of Borrower contained Sections 5.3, 5.4 and 5.5 of this Agreement
shall be referred to as the “Cooperation Covenants”. 
 ARTICLE 6 

MISCELLANEOUS 
 6.1 Survival of Provisions. Except as expressly otherwise provided, the covenants, acknowledgments, representations, agreements and obligations in this Agreement shall survive the payment in
full of the Loan. 
 6.2 No Limitation of Remedies. No right, power or remedy conferred upon or reserved to or by
Lender in this Agreement is intended to be exclusive of any other right, power or remedy conferred upon or reserved to or by Lender under this Agreement, the Loan Documents or at law. Each and every remedy shall be cumulative and concurrent, and
shall be in addition to each and every other right, power and remedy given under this Agreement, the Loan Documents or now or subsequently existing in equity or at law. 
 6.3 No Waivers. Except as otherwise expressly set forth in this Agreement, nothing contained in this Agreement shall constitute a waiver of any rights or remedies of Lender under the Loan
Documents, in equity or at law. No delay or failure on the part of any Party in the exercise of any right or remedy under the Loan Documents or this Agreement shall operate as a waiver, and no single or partial exercise of any right or remedy shall
preclude other or further exercise thereof or the exercise of any other right or remedy. No action or forbearance by any Party contrary to the provisions of the Loan Documents or this Agreement shall be construed to

  
 14 

 
constitute a waiver of any of the express provisions. Any Party may in writing expressly waive any of such Party’s rights under this Agreement or the Loan Documents without invalidating this
Agreement or the Loan Documents. 
 6.4 Successors or Assigns. Whenever any Party is named or referred to in this
Agreement, the heirs, executors, legal representatives, successors, successors-in-title and assigns of such Party shall be included. All covenants and agreements in this Agreement shall bind and inure to the benefit of the heirs, executors, legal
representatives, successors, successors-in-title and assigns of the Parties, whether so expressed or not. 
 6.5
Construction of Agreement. Each Party acknowledges that it has participated in the negotiation of this Agreement. No provision of this Agreement shall be construed against or interpreted to the disadvantage of any Party by any court or
other governmental or judicial authority by reason of such Party having or being deemed to have structured, dictated or drafted such provision. Borrower at all times has had access to an attorney in the negotiation of the terms of and in the
preparation and execution of this Agreement. Borrower has had the opportunity to review and analyze this Agreement for a sufficient period of time prior to execution and delivery. No representations or warranties have been made by or on behalf of
Lender, or relied upon by Borrower, pertaining to the subject matter of this Agreement, other than those set forth in this Agreement. All prior statements, representations and warranties, if any, are totally superseded and merged into this
Agreement, which represents the final and sole agreement of the Parties with respect to the subject matters of this Agreement. All of the terms of this Agreement were negotiated at arm’s length, and this Agreement was prepared and executed
without fraud, duress, undue influence or coercion of any kind exerted by any of the Parties upon the others. The execution and delivery of this Agreement is the free and voluntary act of Borrower. 

6.6 Invalid Provision to Affect No Others. If, from any circumstances whatsoever, fulfillment of any provision of this
Agreement or any related transaction at the time performance of such provision shall be due, shall involve transcending the limit of validity presently prescribed by any applicable usury statute or any other applicable law, with regard to
obligations of like character and amount, then ipso facto, the obligation to be fulfilled shall be reduced to the limit of such validity. If any clause or provision operates or would prospectively operate to invalidate this Agreement, in whole or in
part, then such clause or provision only shall be deemed deleted, as though not contained, and the remainder of this Agreement shall remain operative and in full force and effect. 

6.7 Usury. This Agreement and all other agreements made by Borrower relating directly or indirectly to the Indebtedness are
expressly limited so that in no event or contingency whatsoever shall the amount of interest received, charged or contracted for by Lender exceed the highest lawful amount of interest permissible under the laws of the State. If, under any
circumstances whatsoever, performance of any provision of the Note, the other Loan Documents or this Agreement, at the time performance of such provision shall be due, shall result in the highest lawful rate of interest permissible under the laws of
the State being exceeded, then ipso facto, the amount of interest received, charged or contracted for by Lender shall be reduced to the highest lawful amount of interest permissible under the laws of the State, and if for any

  
 15 

 
reason whatsoever, Lender shall ever receive, charge or contract for, as interest, an amount which would be deemed unlawful, such amount of interest deemed unlawful shall be applied to principal
(whether or not due and payable) or refunded to Borrower (if all principal has been paid) and not to the payment of interest. 

6.8 Indemnity. Borrower agrees to indemnify and hold harmless Lender from any liabilities, costs, expenses (including
attorneys and paralegal fees at all tribunal levels) or claims of the State or any other governmental agency for documentary stamps, intangible taxes and any interest or penalties thereon which may be or become due in connection with (a) the
execution, delivery or recording of this Agreement or (b) the transactions contemplated by this Agreement. 
 6.9
Notices. Any and all notices, elections, approvals, consents, demands, requests and responses (“Communications”) permitted or required to be given under this Agreement or the Loan Documents shall not be effective
unless in writing, signed by or on behalf of the Party giving the same, and sent by hand delivery or overnight courier service (such as Federal Express), to the Party to be notified at the address of such Party set forth below or at such other
address within the continental United States as such other Party may designate by notice specifically designated as a notice of change of address and given in accordance with this Section. Any Communications shall be effective upon the earlier of
their receipt or three days after mailing in the manner indicated in this Section. Receipt of Communications shall occur upon actual delivery but if attempted delivery is refused or rejected, the date of refusal or rejection shall be deemed the date
of receipt. Any Communication, if given to Lender, must be addressed as follows, subject to change as provided above: 
 Berkadia
Commercial Mortgage LLC, 
 CMBS Special Request 
 118 Welsh Road 
 Horsham, PA 19044 

Re: JPMCC 2006-LDP7; Loan No. 991077168 
 With a copy to: 
 LNR Partners, LLC 

1601 Washington Avenue, Suite 700 
 Miami Beach, Florida 33139 
 Attn: Director of Servicing 

Re: JPMCC 2006-LDP7; Loan No. 991077168 
 And: 
 Bilzin Sumberg Baena Price & Axelrod LLP 

1450 Brickell Avenue, Suite 2300 
 Miami, Florida 33131-3456 
 Attn: Marjie C. Nealon, Esq. 

  
 16 

 And, if given to Borrower, must be addressed as follows, notwithstanding any other address set forth in the
Loan Documents to the contrary, subject to change as provided above: 
 MECW, LLC 

K-V Pharmaceutical 
 One Corporate Woods Drive 
 Bridgeton, Missouri 63044 

Attn: Thomas McHugh 
 [The following for information purposes only:] 
 Telephone: 314-645-6600

 Facsimile: 314-646-3705 
 Email: tmchugh@kvpharmaceutical.com 
 With a copy to: 

K-V Pharmaceutical 
 One Corporate Woods Drive 
 Bridgeton, Missouri 63044 

Attn: Office of General Counsel 
 [The following for information purposes only:] 
 Telephone: 314-645-6600

 Facsimile: 314-646-3785 
 Email: chintmann@kvphamaceutical.com 
 6.10 Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State. 
 6.11 Future
Negotiations. Borrower acknowledges and agrees that (i) Lender has no obligation whatsoever to discuss, negotiate or to agree to any restructuring of the Loan, or any modification, amendment, restructuring or reinstatement of the Loan
Documents or to forbear from exercising its rights and remedies under the Loan Documents, except as expressly provided in this Agreement; (ii) if there are any future discussions among Lender and Borrower concerning any such restructuring,
modification, amendment or reinstatement, then no restructuring, modification, amendment, reinstatement, compromise, settlement, agreement or understanding with respect to the Loan, the Loan Documents, the Property or any aspect thereof, shall
constitute a legally binding agreement or contract or have any force or effect whatsoever unless and until reduced to writing and signed by authorized representatives of the Parties; and (iii) Borrower Parties shall not assert or claim in any
legal proceedings or otherwise that any such agreement exists except in accordance with the terms of this Section. 
 6.12
Relationship of Parties. The Parties do not intend by this Agreement to create a partnership or a joint venture. Neither this Agreement nor any of the payments herein or in the Note to be made by either Borrower or Lender shall
constitute, or shall be deemed or construed to constitute, Lender a “mortgagee in possession” of the Property or in any manner liable for any goods or services delivered or provided with respect to the Property or in any manner liable to
any third parties. The relationship of Lender to Borrower is that of “lender” and “borrower” and the Parties acknowledge and agree that the obligations of Lender and Borrower set forth herein are not intended to benefit and
should not be relied on by third parties. 

  
 17 

 6.13 Headings. The headings of the articles, sections and subsections of this
Agreement are for the convenience of reference only, are not to be considered a part of this Agreement and shall not be used to construe, limit or otherwise affect this Agreement. 

6.14 Modifications. The terms of this Agreement may not be changed, modified, waived, discharged or terminated orally, but
only by an instrument or instruments in writing, signed by the Party against whom the enforcement of the change, modification, waiver, discharge or termination is asserted. Except as modified by this Agreement, the Loan Documents shall remain
unmodified and in full force and effect. 
 6.15 Time of Essence: Consents. Time is of the essence of this
Agreement and the Loan Documents. Any provisions for consents or approvals in this Agreement shall mean that such consents or approvals shall not be effective unless in writing and executed by Lender. 

6.16 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and
all such counterparts together shall constitute one and the same instrument. This Agreement shall not be binding on either party until executed and delivered by both parties. 
 6.17 Waiver of Trial by Jury. EACH OF BORROWER AND LENDER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE ANY AND ALL RIGHTS IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
BASED ON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT, THE NOTE, THE SECURITY INSTRUMENT, OR ANY OTHER LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN), OR ACTIONS OF ANY OF
BORROWER PARTIES OR LENDER RELATING TO THE LOAN AND THE LENDING RELATIONSHIP WHICH IS THE SUBJECT OF THIS AGREEMENT. THIS PROVISION IS A MATERIAL INDUCEMENT FOR LENDER ENTERING INTO THIS AGREEMENT AND THE OTHER MODIFICATION DOCUMENTS. EACH OF
BORROWER AND LENDER IS HEREBY AUTHORIZED TO FILE A COPY OF THIS PARAGRAPH IN ANY PROCEEDING AS CONCLUSIVE EVIDENCE OF THIS WAIVER BY BORROWER AND LENDER. 
 6.18 No Oral Agreements. The following notice is given to comply with § 432.045 of the Revised Statutes of Missouri: 
 Oral agreements or commitments to loan money, extend credit or to forbear from enforcing repayment of a debt including promises to extend or renew such debt are not enforceable, regardless of the legal
theory upon which it is based that is in any way related to the credit agreement. To protect you (borrower(s)) and us (creditor) from misunderstanding or disappointment, any agreements we reach covering such matters are contained in this writing,
which is the complete and exclusive statement of the agreement between us, except as we may later agree in writing to modify it. 

  
 18 

 As used in this section, the term “this writing” is deemed to include all Loan Documents.

 (REMAINDER OF PAGE INTENTIONALLY LEFT BLANK) 

  
 19 

 The Parties have executed and delivered this Agreement, as of the day and year first above
written. 
  

											
	Witnesses:	 		 	LENDER:
				
		 		 		 	U.S. BANK, NATIONAL ASSOCIATION, AS TRUSTEE FOR THE REGISTERED HOLDERS OF J.P. MORGAN CHASE COMMERCIAL MORTGAGE SECURITIES CORP., COMMERCIAL MORTGAGE PASS-THROUGH
CERTIFICATES, SERIES 2006-LDP7
					
		 		 		 	By:	 	LNR Partners, LLC, a Florida limited liability company, successor by statutory conversion to LNR Partners, Inc., a Florida corporation, as
attorney-in-fact
	 [ILLEGIBLE]
	 		 		 		 	
	Print Name:	 	 [ILLEGIBLE]
	 		 		 	By:	 	 /s/ Larry Golinsky

		 		 		 		 	Name:	 	Larry Golinsky
		 		 		 		 	Title:	 	President
	 /s/ Loxy Fernandez
	 		 		 		 	
	Print Name:	 	 Loxy Fernandez
	 		 		 		 	
					
	STATE OF FLORIDA	 	)	 		 		 	
		 		 	)	 	ss:	 		 	
	COUNTY OF MIAMI-DADE	 	)	 		 		 	

 The foregoing instrument was acknowledged before me this 4 day of AUGUST, 2011, by Larry Golinsky, as
President of LNR Partners, LLC, a Florida limited liability company, successor by statutory conversion to LNR Partners, Inc., a Florida corporation, on behalf of the said company, as attorney-in-fact for U.S. BANK, NATIONAL ASSOCIATION, AS
TRUSTEE FOR THE REGISTERED HOLDERS OF J.P. MORGAN CHASE COMMERCIAL MORTGAGE SECURITIES CORP., COMMERCIAL MORTGAGE PASS-THROUGH CERTIFICATES, SERIES 2006-LDP7 on behalf of the said trustee and trust. He is personally known to me or has produced a
driver’s license as identification. 
  

					
	 [NOTARY STAMP]
 [AFFIX NOTARY STAMP ABOVE]
	 	 /s/ Ciney Torres

	 	NOTARY PUBLIC, STATE OF FLORIDA
	 	 Ciney Torres

	 	Print or Stamp Name of Notary
	 	  
 My Commission Expires:
	 	  
 5/17/12

  
 20 

											
	Witnesses:	 		 		 		 	
		 		 		 	BORROWER:
				
		 		 		 	MECW, LLC, a Delaware limited liability company
	 /s/ Bradley S. Schammel
	 		 		 		 	
	Print Name:	 	 Bradley S. Schammel
	 		 	 By:
	 	K-V Pharmaceutical Company, a Delaware corporation, its sole member
						
		 		 		 		 	By:	 	 /s/ Gregory J. Divis

		 		 		 		 	Gregory J. Divis, President and CEO
	 /s/ Teresa L. Wilson
	 		 		 		 	
	Print Name:	 	 Teresa L. Wilson
	 		 		 		 	
					
	STATE OF MISSOURI	 	)	 		 		 	
		 	)	 	ss:	 		 	
	COUNTY OF ST. LOUIS	 	)	 		 		 	

 I, Debbie A. Lanemann, a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY,
that Gregory J. Divis, the President and CEO of K-V Pharmaceutical Company, a Delaware corporation, the sole member (“Sole Member”) of MECW, LLC, a Delaware limited liability company, who is personally known to me to be the
same person whose name is subscribed to the foregoing instrument as such officer in such sole member appeared before me this day in person and acknowledged that he signed and delivered the said instrument as his own free and voluntary act and as the
free and voluntary act of Sole Member, for the uses and purposes therein set forth. 
 GIVEN under my hand
and Notarial Seal this 8th day of August 2011. 

 

	
	 /s/ Debbie A. Lanemann

	Notary Public

  

					
	My Commission Expires:	 	[NOTARY STAMP]	 	
	  

    12/10/11                    
        
	 	 	

  
 21 

 EXHIBIT A-1 

SPREADER PROPERTY LEGAL DESCRIPTION 
 Parcel 1: Lot 1 of Corporate Woods, as per plat thereof recorded in Plat Book 299 page 88 of the St. Louis County Records. 
 Parcel 3: A tract of land being in part of Sections 2 and 3 of METRO BUSINESS PARK, a Subdivision filed for record in Plat Book 162, Page 6 of the St. Louis County Records and being more particularly
described as follows: Beginning at a point on the East line of Metro Boulevard, 40 feet wide, said point being the Southwest corner of Section 3 of said Metro Business Park; thence along the East line of Metro Boulevard, North 0 degree 08
minutes East 9.37 feet to a point of curve; thence leaving the East line of Metro Boulevard along a curve to the right whose radius point bears South 89 degrees 52 minutes East 25.00 feet from the last mentioned point an arc distance 39.27 feet to
the point of tangent; thence South 89 degrees 52 minutes East 382.51 feet to a point of curve; thence along a curve to the right whose radius point bears South 0 degree 08 minutes West 35.00 feet from the last mentioned point, an arc distance of
29.99 feet to a point of reverse curve; thence along a curve to the left whose radius point bears North 49 degrees 13 minutes 54 seconds East 49.00 feet from the last mentioned point, an arc distance of 41.99 feet to a point, thence South 0 degree
08 minutes West 355.64 feet to a point; thence North 89 degrees 55 minutes West 414.05 feet to a point on a curve on a cul-de-sac of Metro Boulevard; thence along a curve to the left whose radius point bears North 77 degrees 59 minutes 33 seconds
West 49.00 feet from the last mentioned point an arc distance of 71.70 feet to a point of reverse curve; thence Northwardly along a curve to the right whose radius point bears North 18 degrees 09 minutes 51 seconds East 35.00 feet from the last
mentioned point, an arc distance of 43.96 feet to the point of tangent, said point being on the East line of Metro Boulevard; thence along the East line of Metro Boulevard, North 0 degree 08 minutes East, 260.67 feet to the point of beginning.

 Parcel 4: A tract of land being in part of Sections 2 and 3 of METRO BUSINESS PARK, a Subdivision filed for record in Plat Book 162, Page 6
of the St. Louis county Records and being more particularly described as follows: Beginning at a point, said point being the Southeast corner of Section 2 of said Metro Business Park; thence along the South line of said Section 2 of Said
Section 2, North 89 degrees 55 minutes West 217.71 feet to a point; thence leaving said South line, North 89 degrees 55 minutes West 82.32 feet to a point; thence North 0 degree 08 minutes East 355.64 feet to a point on a curve; thence along a
curve to the left whose radius point bears North 0 degree 08 minutes East 49.00 feet from the last mentioned point, an arc distance of 76.97 feet to a point; thence South 89 degrees 52 minutes East 141.92 feet to a point; thence South 16 degrees 34
minutes 42 seconds East 9.53 feet to a point; thence South 39 degrees 04 minutes 50 seconds East 167.88 feet to a point on the East line of Section 2 thence along the East line of Section 2, South 0 degree 05 minutes West 265.18 feet to
the point of beginning. 
 The estate or interest in the land described above is a leasehold estate created by the Lease Agreement between St.
Louis County, Missouri, landlord, and K-V Pharmaceutical Company, a 

 
Delaware corporation, tenant, dated as of December 1, 2005 and ending on December 1, 2019, notice of which is given by the Memorandum of Lease Agreement recorded December 30, 2005
in Book 16995, page 1855 and assigned to MECW, LLC, a Delaware limited liability company, by the Assignment of Lease dated March 23, 2006 and recorded March 24, 2006 as Daily Number 756. 

  
 2 

 EXHIBIT A-2 

ORIGINAL MORTGAGED PROPERTY LEGAL DESCRIPTION 

Parcel 2: A tract of land being all of Lot 18 of Corporate Exchange Plat four, according to the plat thereof recorded in Plat Book
345 page 280 of the St. Louis County Records, and being located in U.S. Survey 131, Township 46 North, Range 5 East of the
5th Principal Meridian, St. Louis County, Missouri.

  
 3 

 EXHIBIT A-3 

AMENDED AND RESTATED MORTGAGED PROPERTY 
 Parcel 1: Lot 1 of Corporate Woods, as per plat thereof recorded in Plat Book 299 page 88 of the St. Louis County Records. 
 Parcel 2: A tract of land being all of Lot 18 of Corporate Exchange Plat four, according to the plat thereof recorded in Plat Book 345 page 280 of the St. Louis County Records, and being located in U.S.
Survey 131, Township 46 North, Range 5 East of the 5th
Principal Meridian, St. Louis County, Missouri. 
 Parcel 3: A tract of land being in part of Sections 2 and 3 of METRO BUSINESS PARK, a
Subdivision filed for record in Plat Book 162, Page 6 of the St. Louis County Records and being more particularly described as follows: Beginning at a point on the East line of Metro Boulevard, 40 feet wide, said point being the Southwest corner of
Section 3 of said Metro Business Park; thence along the East line of Metro Boulevard, North 0 degree 08 minutes East 9.37 feet to a point of curve; thence leaving the East line of Metro Boulevard along a curve to the right whose radius point
bears South 89 degrees 52 minutes East 25.00 feet from the last mentioned point an arc distance 39.27 feet to the point of tangent; thence South 89 degrees 52 minutes East 382.51 feet to a point of curve; thence along a curve to the right whose
radius point bears South 0 degree 08 minutes West 35.00 feet from the last mentioned point, an arc distance of 29.99 feet to a point of reverse curve; thence along a curve to the left whose radius point bears North 49 degrees 13 minutes 54 seconds
East 49.00 feet from the last mentioned point, an arc distance of 41.99 feet to a point, thence South 0 degree 08 minutes West 355.64 feet to a point; thence North 89 degrees 55 minutes West 414.05 feet to a point on a curve on a cul-de-sac of Metro
Boulevard; thence along a curve to the left whose radius point bears North 77 degrees 59 minutes 33 seconds West 49.00 feet from the last mentioned point an arc distance of 71.70 feet to a point of reverse curve; thence Northwardly along a curve to
the right whose radius point bears North 18 degrees 09 minutes 51 seconds East 35.00 feet from the last mentioned point, an arc distance of 43.96 feet to the point of tangent, said point being on the East line of Metro Boulevard; thence along the
East line of Metro Boulevard, North 0 degree 08 minutes East, 260.67 feet to the point of beginning. 
 Parcel 4: A tract of land being in part
of Sections 2 and 3 of METRO BUSINESS PARK, a Subdivision filed for record in Plat Book 162, Page 6 of the St. Louis county Records and being more particularly described as follows: Beginning at a point, said point being the Southeast corner of
Section 2 of said Metro Business Park; thence along the South line of said Section 2 of Said Section 2, North 89 degrees 55 minutes West 217.71 feet to a point; thence leaving said South line, North 89 degrees 55 minutes West 82.32
feet to a point; thence North 0 degree 08 minutes East 355.64 feet to a point on a curve; thence along a curve to the left whose radius point bears North 0 degree 08 minutes East 49.00 feet from the last mentioned point, an arc distance of 76.97
feet to a point; thence South 89 degrees 52 minutes East 141.92 feet to a point; thence South 16 degrees 34 minutes 42 seconds East 9.53 feet to a point; thence South 39 degrees 04 minutes 50 seconds East 167.88 feet to a point on the East line of
Section 2 thence along the East line of Section 2, South 0 degree 05 minutes West 265.18 feet to the point of beginning. 

  
 4 

 EXHIBIT B 

LOAN DOCUMENTS 
 1. Promissory Note dated March 23, 2006, in the original principal amount of $43,000,000.00 (the “Note”), executed by Borrower in favor of Original Lender, and endorsed to the order
of Lender. 
 2. Deed of Trust, Leasehold Deed of Trust, Security Agreement and Fixture Filing, dated as of March 23, 2006,
executed by Borrower in favor of a trustee for the benefit of Original Lender (the “Security Instrument”), filed for record on March 24, 2006, and recorded as Document No. 2006032400757 in Book 17103, Page 4108 with the
St. Louis County Recorder of Deeds, Missouri (the “Records”), and assigned to Lender. 
 3. Assignment of
Leases and Rents dated as of March 23, 2006, executed by Borrower in favor of Original Lender (the “Assignment of Leases and Rents”), filed for record on March 24, 2006, and recorded as Document No. 2006032400773 in
Book 17103, Page 4293 in the Records, and assigned to Lender. 
 4. UCC Financing Statement reflecting Borrower, as debtor, and
Original Lender, as secured party, filed with the Secretary of State of the State of Delaware under File Number 6108459, and assigned to Lender. 
 5. Guaranty dated as of March 23, 2006, executed by Borrower’s Sole Member, Ther-Rx-Corporation, a Missouri corporation (“Ther-Rx”), ETHEX and PDI (individually and collectively
referred to as “Original Guarantor”) in favor of Original Lender and assigned to Lender, as modified by this Agreement. 
 6. Hazardous Substances Indemnification Agreement dated as of March 23, 2006, executed by Borrower and Original Guarantor in favor of Original Lender (the “Environmental Indemnity”),
and assigned to Lender, as modified by this Agreement. 
 7. Partial Assignment and Assumption Agreement dated as of
March 23, 2006, executed by Borrower and Borrower’s Sole Member. 
 8. Waiver of Manager’s Agreement,
Subordination and Consent to Assignment dated as of March 23, 2006, executed by Borrower and Original Lender. 
 9. Cash
Management Agreement dated as of March 23, 2006, executed by Borrower and Original Lender. 

  
 5 

 JOINDER BY AND AGREEMENT OF CURRENT GUARANTOR 

Each of the undersigned, K-V PHARMACEUTICAL COMPANY, a Delaware corporation and THER-RX-CORPORATION, a Missouri corporation
(being collectively and individually “Current Guarantor”), being guarantor(s) of the Loan (as such term is defined in that certain Note, Deed of Trust, Leasehold Deed of Trust, Security Agreement and Fixture Filing and Other Loan
Documents Modification and Spreader Agreement of even date herewith by and between U.S. Bank, National as trustee for the registered holders of J.P. Morgan Chase Commercial Mortgage Securities Corp., Commercial Mortgage Pass-Through Certificates,
Series 2006-LDP7, as “Lender”, and MECW, LLC, a Delaware limited liability company, as “Borrower” (the “Modification Agreement”)) pursuant to that certain Guaranty dated as of March 23, 2006,
executed by Current Guarantor and others in favor of Original Lender (the “Guaranty”), and indemnitors under that certain Hazardous Substances Indemnification Agreement executed by Current Guarantor, Borrower and others in favor of
Original Lender (the “Environmental Indemnity”), as both are now held by Lender, hereby represents and warrants and acknowledges and agrees with Lender the following: 

1. Reaffirmation of Guaranty and Environmental Indemnity. The Guaranty and the Environmental Indemnity constitute the
valid, legally binding joint and several obligations of Current Guarantor, enforceable against Current Guarantor, in accordance with their respective terms. By their execution hereof, Current Guarantor waives and releases any and all defenses,
affirmative defenses, setoffs, claims, counterclaims and causes of action of any kind or nature which any Current Guarantor has asserted, or might assert, against any of Lender Parties which in any way relate to or arise out of the Guaranty, the
Environmental Indemnity or any of the other Loan Documents. Each Current Guarantor consents to the execution and delivery of the Modification Agreement by Borrower and agrees and acknowledges that the liability of Current Guarantor under the
Guaranty and the Environmental Indemnity shall not be diminished in any way by the execution and delivery of the Modification Agreement or by the consummation of any of the transactions contemplated thereby. 

2. Modification of Guaranty. The Guaranty is modified to provide that the term “Guaranteed Obligations”
under the Guaranty shall include fraud and/or intentional misrepresentation by Borrower in the Modification Agreement. 
 3.
Cooperation Covenants. Without limiting the terms of the Guaranty, Current Guarantor agrees that the Guaranty is further modified to provide that any failure of Borrower after a Default to comply, or any attempt by Current Guarantor
after a Default to interfere with Borrower’s compliance, with the Cooperation Covenants shall subject Current Guarantor to recourse for the Indebtedness. 
 4. Authority Representations by Current Guarantor. The execution and delivery of, and performance under, this Joinder by and Agreement of Current Guarantor, the Guaranty and Environmental
Indemnity by Current Guarantor will not (a) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in 

 
effect having applicability to Current Guarantor or (b) result in a breach of or constitute or cause a default under any indenture, agreement, lease or instrument to which Released Guarantor
is a party or by which the Property may be bound or affected 
 5. Waiver of Trial by Jury. CURRENT GUARANTOR HEREBY
KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE ANY AND ALL RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED ON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT, THE NOTE, THE SECURITY INSTRUMENT, OR ANY OTHER
LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN), OR ACTIONS OF CURRENT GUARANTOR OR LENDER RELATING TO THE LOAN AND THE LENDING RELATIONSHIP WHICH IS THE SUBJECT OF THIS AGREEMENT. THIS PROVISION IS
A MATERIAL INDUCEMENT FOR LENDER ENTERING INTO THIS AGREEMENT AND THE OTHER MODIFICATION DOCUMENTS. LENDER IS HEREBY AUTHORIZED TO FILE A COPY OF THIS PARAGRAPH IN ANY PROCEEDING AS CONCLUSIVE EVIDENCE OF THIS WAIVER BY CURRENT GUARANTOR.

 6. Defined Terms. All terms that are used herein that are not defined herein shall have the meaning ascribed to them
in the Modification Agreement. 
 (REMAINDER OF PAGE INTENTIONALLY LEFT BLANK) 

  
 2 

 The undersigned Current Guarantor has executed and delivered this Joinder and Agreement to
be effective as of the Effective Date of the Modification Agreement. 
  

									
		 		 		 	CURRENT GUARANTOR:
			
	Witnesses:	 		 	K-V PHARMACEUTICAL COMPANY,
		 		 		 	a Delaware corporation
	 /s/ Bradley S. Schammel
	 		 		 	
	Print Name:	 	 Bradley S. Schammel
	 		 		 	
					
		 		 		 	By:	 	 /s/ Gregory J. Divis

		 		 		 		 	Gregory J. Divis, President and CEO
	 /s/ Daniel J. Bollinger
	 		 		 	
	Print Name:	 	 Daniel J. Bollinger
	 		 		 	
				
	STATE OF MISSOURI	 	)	 		 	
		 	)        ss:	 		 	
	COUNTY OF ST. LOUIS	 	)	 		 	

 I, Debbie A. Lanemann, a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY,
that Gregory J. Divis, the President and CEO of K-V Pharmaceutical Company, a Delaware corporation, who is personally known to me to be the same person whose name is subscribed to the foregoing instrument as such officer appeared before me this day
in person and acknowledged that he signed and delivered the said instrument as his own free and voluntary act and as the free and voluntary act of vice president and chief financial officer, for the uses and purposes therein set forth. 

GIVEN under my hand and Notarial Seal this 8th day of Aug., 2011. 

 

	
	 /s/ Debbie A. Lanemann

	Notary Public

 My Commission Expires: 
  

					
	 12/10/13
	 		  	[NOTARY STAMP]

  
 3 

 The undersigned Current Guarantor has executed and delivered this Joinder and Agreement to
be effective as of the Effective Date of the Modification Agreement. 
  

									
		  		 		 	CURRENT GUARANTOR:
			
	Witnesses:	 		 	 THER-RX CORPORATION, a Missouri
 corporation

				
		 		 	By:	 	 /s/ Gregory J. Divis

	 /s/ Bradley S. Schammel
	 		 		 	Gregory J. Divis, President and CEO
	Print Name:	  	 Bradley S. Schammel
	 		 		 	
				
	 /s/ Daniel J. Bollinger
	 		 		 	
	Print Name:	  	 Daniel J. Bollinger
	 		 		 	
				
	STATE OF MISSOURI	 	)	 		 	
		 	)        ss:	 		 	
	COUNTY OF ST. LOUIS	 	)	 		 	

 I, Debbie A. Lanemann, a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY,
that Gregory J. Divis, the President and CEO of Ther-Rx Corporation, a Missouri corporation, who is personally known to me to be the same person whose name is subscribed to the foregoing instrument as such officer appeared before me this day in
person and acknowledged that he signed and delivered the said instrument as his own free and voluntary act and as the free and voluntary act of vice president, for the uses and purposes therein set forth. 

GIVEN under my hand and Notarial Seal this 8th day of Aug., 2011. 

 

	
	 /s/ Debbie A. Lanemann

	Notary Public

 My Commission Expires: 
  

					
	 12/10/13
	 		  	[NOTARY STAMP]

  
 4 

 JOINDER BY AND AGREEMENT OF RELEASED GUARANTOR 

The undersigned, PARTICLE DYNAMICS, INC., a New York corporation and ETHEX CORPORATION, a Missouri Corporation
(being collectively and individually the “Released Guarantor”) being a Guarantor under the Guaranty and an Indemnitor under the Environmental Indemnity executed in connection with the Loan described in the Note, Deed of Trust,
Leasehold Deed of Trust, Security Agreement and Fixture Filing and Other Loan Documents Modification and Spreader Agreement (“Modification Agreement”) to which this Joinder (“Released Guarantor Joinder”) is
attached, hereby represents and warrants to, and acknowledges and agrees with, Lender the following: 
 1. Defined
Terms. All capitalized terms used in this Released Guarantor Joinder, unless defined herein, shall have the meanings given such terms in the Modification Agreement. 
 2. Reaffirmation of Guaranty and Environmental Indemnity. The Guaranty and Environmental Indemnity constitute the valid, legally binding joint and several obligation of Released Guarantor,
enforceable against Released Guarantor in accordance with their respective terms. By Released Guarantor’s execution hereof, Released Guarantor waives and releases any and all defenses, affirmative defenses, setoffs, claims, counterclaims and
causes of action of any kind or nature which Released Guarantor has asserted, or might assert, against any of Lender Parties which in any way relate to or arise out of the Guaranty and Environmental Indemnity or any of the other Loan Documents.

 3. Agreements of Released Guarantor. Released Guarantor consents to the execution and delivery of the
Modification Agreement by Borrower and agrees and acknowledges that, except as set forth in paragraphs 5 and 6 below, the liability of Released Guarantor under the Guaranty and Environmental Indemnity shall not be diminished in any way by the
execution and delivery of the Modification Agreement or by the consummation of any of the transactions contemplated therein, including but not limited to the Requested Actions. 

4. Authority Representations by the Released Guarantor. The execution and delivery of, and performance under, this Released
Guarantor Joinder, the Guaranty and Environmental Indemnity by Released Guarantor will not (a) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having
applicability to Released Guarantor or (b) result in a breach of or constitute or cause a default under any indenture, agreement, lease or instrument to which Released Guarantor is a party or by which the Property may be bound or affected.

 5. Release of Released Guarantor under Guaranty. Notwithstanding anything to the contrary in this Released
Guarantor Joinder, the Security Instrument, or the other Loan Documents, Released Guarantor’s obligations hereunder and under the Guaranty shall not apply with respect to, and by acceptance of this Released Guarantor Joinder, Lender agrees that
Released Guarantor is hereby released from any and all of Released Guarantor’s obligations under the Guaranty (the “Guaranteed Obligations”) for acts or events occurring or obligations

  
 5 

 
arising after the Effective Date except: (i) if such Guaranteed Obligations are caused by Released Guarantor and/or any of their agents, and (ii) the environmental obligations under the
Guaranty (“Environmental Indemnity Obligations Under Guaranty”) occurring after the Effective Date if such Environmental Indemnity Obligations Under Guaranty are (a) caused by Released Guarantor and/or any of their agents or
(b) result from the existence of conditions existing prior to the Execution Date or migrating to or from any portion of the Property prior to the Effective Date, or result from a violation of Environmental Laws (as defined in the
Environmental Indemnity) prior to the Effective Date. For purposes of this Released Guarantor Joinder, Released Guarantor shall bear the burden of proving when Hazardous Substances (as defined in the Environmental Indemnity) first existed
upon, about or beneath the Property or began migrating to or from the Property and when a violation of Environmental Laws first occurred; provided however, the foregoing burden of proof is for the benefit of Lender, its successors and
assigns, and is not for the benefit of any third party. 
 6. Release of Released Guarantor Under Environmental
Indemnity. Notwithstanding anything to the contrary in this Released Guarantor Joinder, the Security Instrument or the Loan Documents, Released Guarantor’s obligations hereunder and under the Environmental Indemnity shall not apply with
respect to, and by acceptance of this Released Guarantor Joinder, Lender agrees that Released Guarantor is hereby released for all acts or events occurring or obligations arising under the Environmental Indemnity (“Environmental Indemnity
Obligations”) after the Effective Date unless such Environmental Indemnity Obligations are: (i) caused by Released Guarantor and/or any of their agents, or (ii) result from the existence of conditions existing prior to the
Effective Date or migrating to or from any portion of the Property prior to the Effective Date, or result from a violation of an Environmental Law prior to the Effective Date. For purposes of this Released Guarantor Joinder, Released Guarantor shall
bear the burden of proving when a Hazardous Substance existed upon, about or beneath the Property or began migrating to or from the Property and when a violation of an Environmental Law first occurred; provided however, the foregoing burden of proof
is for the benefit of Lender, its successors and assigns, and is not for the benefit of any third party. 
 (REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK) 

  
 6 

 The undersigned Released Guarantor has executed and delivered this Released Guarantor
Joinder to be effective as of the date of the Agreement. 
  

									
	Witnesses:	 		 	RELEASED GUARANTOR:
			
	 /s/ Bradley S. Schammel
	 		 	PARTICLE DYNAMICS, INC., a New
	Print Name:	 	 Bradley S. Schammel
	 		 	York corporation
				
	 /s/ Daniel J. Bollinger
	 		 	By:	 	 /s/ Gregory J. Divis

	Print Name:	 	 Daniel J. Bollinger
	 		 	Name:	 	 Gregory J. Divis

		 		 		 	Title:	 	 President

				
	STATE OF MISSOURI	 	)	 		 	
		 	)        ss:	 		 	
	COUNTY OF ST. LOUIS	 	)	 		 	

 I, Debbie A. Lanemann, a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY,
that Gregory J. Divis the President of Particle Dynamics, Inc., a New York corporation, who is personally known to me to be the same person whose name is subscribed to the foregoing instrument as such officer appeared before me this day in person
and acknowledged that he signed and delivered the said instrument as his own free and voluntary act and as the free and voluntary act of vice president, for the uses and purposes therein set forth. 

GIVEN under my hand and Notarial Seal this 8th day of Aug., 2011. 

 

	
	 /s/ Debbie A. Lanemann

	Notary Public

  

					
	My Commission Expires:	 		  	
			
	 12/10/13
	 		  	[NOTARY STAMP]

  
 7 

 The undersigned Released Guarantor has executed and delivered this Released Guarantor
Joinder to be effective as of the date of the Agreement. 
  

									
	Witnesses:	 		 	RELEASED GUARANTOR:
			
	 /s/ Bradley S. Schammel
	 		 	ETHEX CORPORATION., a Missouri
	Print Name:	 	 Bradley S. Schammel
	 		 	corporation
				
	 /s/ Daniel J. Bollinger
	 		 	By:	 	 /s/ Gregory J. Divis

	Print Name:	 	 Daniel J. Bollinger
	 		 	Name:	 	 Gregory J. Divis

		 		 		 	Title:	 	 President

				
	STATE OF MISSOURI	 	)	 		 	
		 	)        ss:	 		 	
	COUNTY OF ST. LOUIS	 	)	 		 	

 I, Debbie A. Lanemann, a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY,
that                     , the
                    of ETHEX Corporation, a Missouri corporation, who is personally known to me to be the same person whose name is subscribed to the
foregoing instrument as such officer appeared before me this day in person and acknowledged that he signed and delivered the said instrument as his own free and voluntary act and as the free and voluntary act of vice president, for the uses and
purposes therein set forth. 
 GIVEN under my hand and Notarial Seal this 8th day of Aug., 2011. 

 

	
	 /s/ Debbie A. Lanemann

	Notary Public

  

					
		 		  	
	My Commission Expires:	 		  	
			
	 12/10/13
	 		  	[NOTARY STAMP]

  
 8 

 JOINDER OF LENDER TO RELEASED GUARANTOR JOINDER 

The undersigned joins in the Released Guarantor Joinder to which this Joinder is attached solely to consent to the release described in
and subject to the terms of paragraphs 5 and 6 of the Released Guarantor Joinder to which this Joinder is attached. 
 Unless
defined herein, all capitalized terms used herein shall have the meanings given such terms in the Modification Agreement. 

Dated this 4th day of August, 2011. 
  

											
	Witnesses:	 		 	LENDER:
			
		 		 	U.S. BANK, NATIONAL ASSOCIATION, AS TRUSTEE FOR THE REGISTERED HOLDERS OF J.P. MORGAN CHASE COMMERCIAL MORTGAGE SECURITIES CORP., COMMERCIAL MORTGAGE PASS-THROUGH
CERTIFICATES, SERIES 2006-LDP7
				
		 		 	By:	 	LNR Partners, LLC, a Florida limited liability company, successor by statutory conversion to LNR Partners, Inc., a Florida corporation, as
attorney-in-fact
					
	 [ILLEGIBLE]
	 		 		 		 	
	Print Name:	 	 [ILLEGIBLE]
	 		 		 	By:	 	 /s/ Larry Golinsky

		 		 		 		 	Name:	 	Larry Golinsky
		 		 		 		 	Title:	 	President
					
	 /s/ Loxy Fernandez
	 		 		 		 	
	Print Name:	 	 Loxy Fernandez
	 		 		 		 	

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]